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DETERMINATION OF NOVEL METABOLITES OF THERAPEUTIC
AGENTS USED IN THE TREATMENT OF CASTRATION-RESISTANT
PROSTATE CANCER
MOHAMMAD ALYAMANI
ABSTRACT
Despite an array of improved treatment options over the past decade, prostate
cancer remains the second leading cause of cancer mortality for men in the United States.
Abiraterone and galeterone are oral steroidal compounds that are used to treat metastatic
castration-resistant prostate cancer (CRPC). Abiraterone blocks 17α-hydroxylase/17,20lyase (CYP17A1), an enzyme required for androgen synthesis. Galeterone inhibits
CYP17A1, blocks the androgen receptor (AR), and decreases AR protein levels. Both
drugs

share

the

same

structure

with

endogenous

androgens

such

as

dehydroepiandrosterone, which are substrates for the enzyme, 3β-hydroxysteroid
dehydrogenase (3βHSD). Metabolites of 3βHSD undergo further metabolism to produce
the AR ligand, testosterone and dihydrotestosterone.
Overall this project aimed to investigate the steroidogenic metabolism of
abiraterone and galeterone and evaluate the metabolites’ role in prostate cancer. The
background on prostate cancer, steroid biosynthesis, and treatment options is described in
Chapter I. Chapter II describes the development and validation of a liquid chromatography
mass spectrometry method LC-MS/MS to determine abiraterone metabolites. My method
distinguished between all the diastereoisomers with conventional chromatographic

vi

conditions. In chapter III and IV my validated LC-MS/MS method was utilized to study
the metabolism of abiraterone in vitro using prostate cancer cell lines and in vivo using
mice. It also helped in determining abiraterone metabolites in a pharmacokinetic trial in
healthy human subjects and in prostate cancer patients enrolled in several clinical trials.
The trials aimed to evaluate the standard dose of abiraterone acetate, combining abiraterone
acetate with androgen deprivation therapy (ADT), adding dutasteride (an SRD5A
inhibitor), or increasing the frequency of the standard dose of abiraterone acetate. In
chapter V, galeterone metabolism was studied in vitro and in vivo and the metabolites’
activities were evaluated for their roles in prostate cancer. Chapter VI discusses the overall
conclusions and future directions.
This project identified a new subset of abiraterone and galeterone metabolites that
are generated by steroidogenic enzyme conversion. These metabolites had opposing
effects on prostate cancer. These findings suggest a common pathway for steroidal drugs
with a Δ5, 3β-hydroxyl structure. This project also provides new strategies in prostate
cancer treatment that will make the current treatment options more beneficial.
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CHAPTER I
PROSTATE CANCER: AN OVERVIEW

1.1.

Background
“A very rare disease” is how J. Adams, the surgeon at The London Hospital,

described the first case of prostate cancer, which he discovered by histological examination
in 18531. After more than 160 years, prostate cancer is the most frequently diagnosed
cancer and the third leading cause of cancer death in men in the United States. One out of
seven American men will be diagnosed with prostate cancer during their lifetime. In 2017,
it is estimated that 160,000 American men will be diagnosed with prostate cancer and
26,000 will lose their lives to the disease2.
The prostate gland is part of the male reproductive system. It is a walnut size and
shaped organ. It sits below the bladder just in front of the rectum and surrounds part of
the urethra. The role of the prostate is to help make the semen. Even though researchers do
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not know exactly what causes prostate cancer, several factors can be linked to it: age,
ethnicity, heredity, and geographic region3. The older the man is, the higher the possibility
of being diagnosed with prostate cancer. According to recent statistics from the Prostate
Cancer Foundation, 65% of prostate cancer patients are older than 65 years old. Compared
with Caucasian and Asian men, African American men are more likely to develop prostate
cancer and are more likely to die from the disease. The chance of being diagnosed with
prostate cancer will double if a man has a father or brother who developed prostate cancer.
Those who live in the northern part of the United States are at higher risk to develop and
die from the disease. Although why this pattern exists is unclear, it may be that low
exposure to sun light and vitamin D deficiency can increase the disease rates4. Other factors
that can be linked to prostate cancer include diet, obesity, and smoking5.
1.2.

The Androgen Receptor
Prostate cancer is a hormone-dependent malignancy; tumor progression depends

on androgen receptor AR presence and function6,7. AR belongs to the steroid hormone
group of nuclear receptors, along with the estrogen receptor (ER), glucocorticoid receptor
(GR), progesterone receptor (PR) and mineralocorticoid receptor (MR)8. Testosterone (T)
and its more potent metabolite, 5α-dihydrotestosterone (DHT), are the ligands for
activating the AR. Therefore, these two steroids are the endogenous ligands fueling the
growth of malignant prostate cells. DHT is 10 times more potent than T in activating the
AR9. AR protein is encoded by the AR gene located on the X chromosome at Xq11-12 and
spans ~180 kb of DNA containing 8 canonical exons. The AR contains four domains: (I)
the amino terminal activation domain (NTD); (II) the DNA-binding domain (DBD); (III)
the hinge region (HR) and (IV), the carboxyl ligand-binding domain (LBD). NTD, which
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is encoded by exon 1, is the transcriptional regulatory region of the AR containing
activation function-1 (AF-1). The DBD, composed of two zinc finger motifs, is encoded
by exons 2 and 3, respectively. The hinge region is encoded by exon 4. The LBD is encoded
by exons 5–8 and contains activation function-2 (AF-2) that allows the recruitment of coactivators and co-repressors (Fig 1). The transcriptional activity of the AR requires AF-1
in its NTD with negligible activity being attributed to AF-2 region in the LBD10,11.
When androgens such as DHT diffuse through the plasma membrane of the cell and
bind to the LBD of AR, they will initiate cellular events involving conformational changes,
receptor stabilization, and nuclear translocation. It will also result in binding of AR dimer
to androgen response elements (AREs) located in the promoter and enhancer sequences of
target genes. AR binds target AREs via its DBD; a portion of the DBD together with the
hinge region encode for a nuclear localization signal (NLS)12,13 (Fig. 2).
1.3.

Regulation of Testosterone Synthesis by the Endocrine Axis
The major source of circulating testosterone are the testes; however the adrenal

gland can also produce T by regulating androgen biosynthesis. The endocrine axis
contributes to the growth of prostate cancer by regulating T synthesis in these two sources:
(i) the hypothalamus-pituitary-gonadal axis (HPG axis) and (ii) the hypothalamuspituitary-adrenal axis (HPA axis)14,15. In the hypothalamus, gonadotropin-releasing
hormone (GnRH), also known as luteinizing hormone (LH)-releasing hormone (LHRH),
is produced and travels to the anterior pituitary and interacts with LHRH receptors (LHRHRs). Due to this interaction, LH will be released into the blood stream. In the testes, the
released LH binds to its receptors (LH-R), inducing T production. The hypothalamus also
produces corticotropin-releasing hormone (CRH). CRH stimulates the secretion of
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adrenocorticotropic hormone (ACTH) from the pituitary into the blood stream where it
interacts with the adrenal cortex portion of the adrenal gland and stimulates the synthesis
of adrenal androgens, including T (Fig 3). T synthesized and released from both sites enters
the prostate cells, where it is converted to 5α-dihydrotestosterone (DHT) by the enzyme
5α-reductase SRD5A. DHT binds tightly to AR, enters the cytoplasm, and the complex
translocates to the nucleus, where it activates transcription of genes that regulate cell
growth and survival.

4

Figure 1. Genomic organization of the AR gene.
(Source: Quigley, C. A,1995)11
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Figure 2. Ligand-dependent activation of the AR.
CBP (CREB-binding protein); hsp (heat shock protein); SRC-1 (steroid receptor
coactivator 1) (Source: Meehan, K. L; 2003)12.
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Figure 3. The regulation of androgen synthesis by the HPA and HPG axes.
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1.4.

Steroid Biosynthesis (Steroidogenesis)
Cholesterol is the precursor for steroid biosynthesis16,17. This 27-carbon compound

can be oxidized to 21-carbon steroids (progestins, glucocorticoids, and mineralocorticoids)
that then can form 19-carbon androgens. As discussed in section 1.3, the two primary
sources of androgens are the adrenal cortex and the Leydig cells. Enzymes involved in
steroidogenesis are either part of the cytochrome P450 (CYP) system, which is a group of
oxidative enzymes that contain a single heme group and almost 500 amino acids18, or
hydroxysteroid dehydrogenases (HSDs), which contain heme groups and require
nicotinamide adenine dinucleotide as a cofactor for their activity. Structurally, HSDs
belong to two groups of enzymes: the short-chain dehydrogenase reductase (SDR) family
or the aldo-keto reductase (AKR) family19. CYP reactions are irreversible, meaning that
the accumulation of product will not drive flux to its precursor. On the other hand, some
HSD reactions are reversible. The first step of steroidogenesis is catalyzed by CYP11A1,
which results in side chain cleavage of cholesterol to pregnenolone (Fig. 4). CYP17A1
(17α-hydroxylase and 17,20 lyase) converts pregnenolone to 17 hydroxy-pregnenolone
and then to dehydroepiandrosterone (DHEA). 3β-hydroxysteroid dehydrogenase/Δ5-Δ4
isomerase (3βHSD) irreversibly converts 3β-OH, Δ5 steroids to 3-keto, Δ4 steroids. Two
isoforms of 3βHSD are present in human, with 3βHSD1 being the isoenzyme dominantly
expressed in peripheral tissue. This enzyme converts pregnenolone to progesterone, 17hydroxypregnenolone to 17-hydroxyprogesterone, DHEA to androstendione (AD), and Δ5Androstenediol (A5diol) to T.
The Sharifi lab reported that in CRPC a mutation in the gene coding for 3βHSD
results in increased DHT levels20. Steroid-5α-reductase (SRD5A) converts 3-keto, Δ4
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steroids to 5α-reduced steroids. Two isoforms of SRD5A are present in human. This
enzyme converts AD to 5α-androstanedione (5α-dione) and T to DHT. It has been reported
that in CRPC, conversion of AD to T is less favored and DHT synthesis requires conversion
of AD to 5α-dione, where AD is the favored 5α-reductase substrate21. 17β-hydroxysteroid
dehydrogenase (17βHSD) reversibly converts 17 keto-androgens to 17 hydroxyandrogens. Fourteen 17βHSD isoenzymes are present in humans; some have a preference
for the reductive reaction (17-keto to 17-hydroxyl) and some prefer the reverse reaction. In
males, 17βHSD3 is the isoenzyme responsible for T synthesis in the testes. However, in
CRPC, 17βHSD5, also known as the aldo-keto reductase 1C3, another reductive enzyme
and converts AD to T, is up-regulated22,23. 3α-hydroxysteroid dehydrogenase (3αHSD) is
also an aldo-keto reductase; it has four isoenzymes and although it is required for
converting active steroids to inactive steroids, it can be involved in the backdoor DHT
synthesis pathway24,25.

9

Figure 4. DHT synthesis pathways.
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1.5.

The Development of Castration-Resistant Prostate Cancer
Prostate cancer develops in stages. In its early stages the tumor is found in the

prostate only. In this stage, prostate cancer is microscopic; it cannot be felt on a digital
rectal exam (DRE), and it is not seen on imaging of the prostate. The tumor then spreads
but still inside the prostate and does not extend beyond it. After that the tumor will spread
outside the prostate but only barely, and may involve the nearby tissues like the seminal
vesicles. In its latest stages the tumor will spread (metastasize) outside the prostate to other
tissues (lymph nodes, the bones, liver, or lungs). The treatment option will depend on the
stage: active surveillance, radical prostatectomy, or radiation therapy (external beam or
brachytherapy) are the options for localized disease. In the advanced stages, chemotherapy
and hormonal therapy are the options. Hormonal therapy is the gold standard for treating
patients with prostate cancer26-28. The discoveries of Charles Huggins concerning hormonal
therapy to treat prostate cancer led him to win Nobel Prize in 1966. In his early research,
Huggins found that castration or estrogen administration shrinks the tissue29,30. His
discoveries led to what is known now as androgen deprivation therapy, or ADT, which can
be achieved either by surgical castration (orchiectomy) or medical castration using a GnRH
agonist or antagonist. ADT will lower serum T levels and it initially works in many cases;
however, the tissue can still find its fuel which leads it to resist this treatment and the tumor
will develop to the castration-resistant prostate cancer CRPC stage22,31,32. Secondgeneration hormone therapies such as abiraterone acetate and enzalutamide are treatment
options at the CRPC stage33-36 (Fig 5A&B).
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Figure 5. Treatment options for prostate cancer
(Source; Gomez, L. 2015)28
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1.6.

Abiraterone
Abiraterone [abi; 17-(3-pyridyl)-androsta-5,16-dien-3β-ol] is a 17-heteroazole

steroidal compound and a potent inhibitor of steroid 17α-hydroxylase/17,20-lyase
(CYP17A1), an enzyme required for androgen synthesis37. Abiraterone’s structure makes
it a potent CYP17A1 inhibitor, and the double bond at C16 is necessary for functionally
irreversible inhibition of the enzyme38-40. Abiraterone is administered as the prodrug,
abiraterone acetate (AA), for the treatment of CRPC and prolongs survival for these
patients34,41,42. In 2011, the United States Food and Drug Administration (FDA) approved
AA in the post-chemotherapy setting, and in December 2012 it approved the use of AA for
patients with chemotherapy-naïve CRPC43. Prednisone is administered with AA to block
mineralocorticoid excess that occurs with the simultaneous inhibition of cortisol
synthesis27,44. The major recognized metabolites of abiraterone result from hepatic
CYP3A4 and SULT2A1 processing, forming the N-oxide of abiraterone and abiraterone
sulfate45, respectively. Neither of these modifications affect the Δ5, 3β-hydroxyl-structure
of the steroid backbone.
1.7.

Galeterone
Galeterone (Gal), 17-(1H-benzimidazol-1-yl) androsta-5,16-dien-3β-ol, is a

steroidal 17-azole compound that inhibits CYP17A146-49, directly competes with androgens
to bind and antagonize AR50, promotes AR protein degradation, and has clinical activity as
reported in a phase I/II clinical trial51-55. Galeterone’s structure enables interaction with the
steroid binding site of CYP17 in addition to coordination with the enzyme’s heme iron,
resulting in a highly specific and tightly binding inhibitor. The x-ray crystal structure of
CYP17A1 binding to abiraterone or galeterone shows that they bind to heme iron56.
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Galeterone shares its Δ5, 3β-hydroxyl structure with abiraterone. The two drugs are
distinguished by their C17 moieties – the benzamidazole ring of galeterone and the 3pyridyl structure of abiraterone. These differences may explain why galeterone has been
reported to have more direct effects on AR.
1.8.

Hypothesis
Δ5, 3β-hydroxyl steroids are substrates of the enzyme 3βHSD, which irreversibly

converts them to 3-keto, Δ4 steroids. An example of this is the conversion of DHEA to AD
and A5diol to T. The next step is then 5α reduction of 3-keto, Δ4 steroids by SRD5A to
form 3-keto-5α reduced steroids, as present in T conversion to DHT. AKR1C2 will then
reduce the 3-keto-5α steroids to the 3α-OH-5α steroids. This last step is one mechanism of
DHT elimination. DHT is converted to 5α-androstan-3α,17β-diol (3α-diol) (Fig. 4).
Both abiraterone and galeterone are Δ5, 3β-hydroxyl steroids. Therefore, they can
be possible substrates of 3βHSD and converted to their 3-keto, Δ4 structures, which may
follow the downstream mechanism and be converted to the 5α-reduced form. The main
aim of this project is to study abiraterone and galeterone metabolism by steroidogenic
enzymes and study the activity of the resultant metabolites. The metabolism was studied
in vitro using prostate cancer cell lines and in vivo using NSG mice. I hypothesized that
the enzymes present in prostate cancer cell lines and in mice will convert abiraterone
and galeterone to their steroidogenic enzyme metabolites and this conversion is
irreversible. Galeterone metabolite activity was studied in vitro and in vivo. I
hypothesized that galeterone metabolites will show activity toward the AR signaling
pathway in prostate cancer cell lines, and in mouse models, the metabolites will have
activity directed against tumors in mouse xenograft models. Abiraterone metabolism
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was investigated in patients with CRPC who are treated with abiraterone acetate in clinical
trials. I hypothesized that inhibiting steroidogenic enzymes or increasing the
frequency of abiraterone dose will affect abiraterone metabolite levels in CRPC
patients which may correlate with clinical outcomes.
1.9.
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CHAPTER II
DEVELOPMENT AND VALIDATION OF A NOVEL LC-MS/MS METHOD FOR
SIMULTANEOUS DETERMINATION OF ABIRATERONE AND ITS SEVEN
STEROIDAL METABOLITES IN HUMAN SERUM

2.1.

Introduction to Liquid Chromatography Mass Spectrometry
Due to its sensitivity and selectivity, mass spectrometry-based analysis has been

widely used in different types of research. It can be used to detect both small and large
molecules. Mass spec applications include basic research, clinical research, drug discovery,
forensics, food quality, and environmental protection. Several designs of mass
spectrometers are available: linear ion trap, quadrupole based, time of flight (TOF). Also,
there are hybrid designs: the quadrupole time of flight QTOF and quadrupole ion trap
QTrap1. Mass spec analysis allows one to answer numerous questions, including what is
in the samples and how much of it is there. To be analyzed, the analyte should be charged,
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because mass spec detects mass /charge ratio (m/z). The ionization techniques are electro
spray ionization (ESI), atmospheric pressure chemical ionization, and atmospheric
pressure photo ionization. The selection of the ionization type depends on the nature of the
analyte. Multiple reaction monitoring is the technique that assures that only the analyte of
interest is selected: First, analyzer quadrupole Q1 selects the precursor mass of interest
from ions only of exactly the selected m/z pass to the collision cell Q2; all other ions are
removed. Collision cell Q2 fragments precursor ions. Fragmented ions pass to analyzer
quadrupole Q3. Analyzer quadrupole Q3 selects the most sensitive ion for quantitation
(Fig. 6). Mass spectrometry can be used as a technique by itself or it can be coupled to
liquid chromatography (LC-MS) or gas chromatography (GC-MS). Both techniques are
widely used for metabolism studies; however the advantages of LC-MS over GC-MS
includes simple sample preparation, shorter run times, and high throughput.
Applying LC-MS analysis to detect analytes in human fluids (saliva, blood, serum,
plasma, or urine) requires sample purification. Three methods can be applied to extract the
analyte of interest from different matrices: direct protein precipitation, liquid-liquid
extraction, or solid-phase extraction.
LC-MS methods can be applied to prostate cancer research. As described in chapter
I, prostate cancer depends on steroid synthesis. Therefore, using an LC-MS method that
accurately detects these steroids and quantifies their levels in patient tissue or serum, may
identify potential specific biomarkers2,3. LC-MS methods are useful in detecting drug
metabolites; therefore it may also give a clue to which patients respond to treatment.
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Figure 6. Multiple reaction monitoring principle.
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2.2.

Method Development and Validation
Although mass spec is a useful technique, operating the instrument and developing

the methods requires knowledge and qualifications in separation and ionization. The first
step in developing LC-MS methods is to optimize mass spec parameters, which include
selecting the appropriate ionization technique, selecting m/z for the parent analyte and the
fragment, and selecting the declustering potential, collision energy, and the source
temperature. After optimizing source parameters, the next step is to select suitable
chromatographic conditions, which include type of analytical column, mobile phase
composition, flow rate, and injection volume. Then as a last step, the best method of
extraction is selected that leads to high recovery and minimizes the matrix effect.
Depending on the purpose of analysis the development may also include selecting the linear
range. After testing the developed method for linearity and accuracy, the next stage is
validating the method per the guidelines depending on the type of analysis. The purpose of
the validation is to make sure that the method is accurate and precise and the analytes are
stable at different conditions. Once the validation is completed, the method is ready to be
used for analysis. The development and validation steps are described in Figure 7.
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Figure 7. The approach of developing LC-MS methods
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2.3.

Abiraterone Metabolism by Steroidogenic Enzymes
Abiraterone design was based on its similarity in structure with pregnenolone which

is a CYP17A1 substrate4,5. Since its FDA approval, abiraterone acetate, the prodrug of
abiraterone, became the choice of treatment for patients with CRPC6,7. Abiraterone sulfate
and N-oxide abiraterone sulfate are the reported abiraterone metabolites8. We studied the
effect of steroidogenic enzymes on abiraterone both in vitro and in vivo and found that 3βhydroxysteroid dehydrogenase (3βHSD) converts abiraterone to its Δ4, 3-keto congener
(Δ4-abiraterone; D4A)9. D4A is similar in structure to T which might enable further
metabolism of D4A. D4A undergoes metabolism by two possible pathways: via steroid 5αreductase (SRD5A) or steroid 5β-reductase. The resultant metabolites can also be
metabolized by two enzymes: 3α-hydroxysteroid dehydrogenase (3αHSD) or 3βHSD. The
5α-reduced metabolites are 3-keto-5α-Abi, 3α-OH-5α-Abi and 3β-OH-5α-Abi, while the
corresponding 5β-reduced metabolites are 3-keto-5β-Abi, 3α-OH-5β-Abi and 3β-OH-5βAbi10 (Fig 8).
This chapter describes the development and validation of the LC-MS method that
was used to detect abiraterone and its seven steroidal metabolites in human serum. In this
validated method, the separation of the structurally identical metabolites was achieved
using a reversed-phase chromatographic technique, not requiring a chiral column11. All
these metabolites were also detected in serum samples from patients with CRPC
undergoing treatment with abiraterone acetate.
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Figure 8. Steroidogenic enzyme metabolism of abiraterone.
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2.4.

Experimental Section

2.4.1. Materials
Abiraterone and its seven metabolites 3-keto-Δ4-Abi, 3-keto-5α-Abi, 3α-OH-5αAbi, 3β-OH-5α-Abi, 3-keto-5β-Abi, 3α-OH-5β-Abi and 3β-OH-5β-Abi were synthesized
in the lab as described previously10. The internal standard (abiraterone-d4) was purchased
from Toronto Research Chemicals, (Toronto, Canada). LC-MS grade methanol,
acetonitrile, water, and formic acid were used to prepare the mobile phase and were
purchased from Fisher Scientific (Fair Lawn, NJ); methyl tertiary butyl ether (MTBE) was
used as the extraction solvent was HPLC grade and was purchased from Acros (Pittsburgh,
PA). The control calibrators and all validation samples were prepared by spiking a known
concentration of all analytes in double charcoal-stripped human serum from Golden West
Biological Inc. (Temecula, CA).
2.4.2. Method development
In this section the development of LC-MS based bioanalytical method is described.
The approaches to develop the LC-MS method involve optimizing the mass conditions and
the chromatographic conditions, selecting linear range, and the procedure to prepare the
sample, all of which are described in detail.
2.4.2.1. Instrumentation and data analysis
To analyze the samples, ultra-pressure liquid chromatography coupled to a mass
spectrometer UPLC-MS system was used. The UPLC system (Shimadzu Corporation,
Japan), consisted of an LC-30AD solvent delivery system, a DGU-20A5R vacuum
degasser, a CTO-30A thermostated column oven, SIL-30AC auto-sampler, and a system
CBM-20A controller. The UPLC system was coupled with a Qtrap 5500 mass spectrometer

31

(AB Sciex, Redwood City, CA). Data acquisition and processing were performed using
Analyst software (version 1.6.2) from AB Sciex. The peak area ratio of the analyte over
the internal standard was used for quantification purposes.
2.4.2.2. Optimizing mass spectrometer conditions
The mass spectrometer was operated in positive ion mode using an electrospray
ionization (ESI) source, and applying multiple reaction monitoring (MRM). Tuning
parameters were optimized for the abiraterone metabolites and internal standard by
infusing a solution containing 200 ng/mL of each analyte. After infusing the solution and
selecting the parent ion in Q1, the optimum value of the ion spray voltage, the source
temperature, and the declustering potential were selected. Then the parent ion was
fragmented in Q2 and the fragment ion (daughter ion) was selected along with the collision
energy, entrance potential, and collision exit potential. The mass spectrometer parameters
were optimized to ensure that the highest sensitivity possible would be achieved. Nitrogen
was used as the nebulizing and drying gas.
2.4.2.3. Optimizing chromatographic conditions
Selecting an appropriate analytical column and a suitable mobile phase are the main
factors in optimizing the chromatographic conditions. This will lead to an enhanced peak
shape, increase in the intensity, and most importantly avoid overlap between analytes. In
the case of diaseteoisomers, distinguishing between the metabolites based on their mass
transition is very difficult because they share the same mass transition. Therefore, the
chromatographic conditions are key in distinguishing between the metabolites. Chiral
columns are the choice in dealing with diasterioisomers; however, these types of columns
are not universal and require lot of trial and error experimentation. The challenge here was
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to separate the metabolites using a regular C18 analytical column. Several mobile phases
were evaluated with different compositions of organic modifiers or additives. The
separation also depends on the column temperature, so this factor was also evaluated.
2.4.2.4. Optimization of sample preparation
When dealing with biological samples, the major factor in selecting the extraction
protocol is the recovery of the analyte and also avoiding the matrix effect. Although direct
protein precipitation is fastest and the cheapest, the matrix effect can be an issue and can
lead to ion suppression during the analysis. Solid phase extraction is a useful technique but
it is expensive and requires a long sample processing time. Therefore, here, liquid-liquid
extraction procedure was considered from the beginning and optimized to obtain a high
recovery and clean samples. Methyl tert butyl ether was selected as the organic solvent.
The other solvent that was tested during the extraction was the reconstitution solvent.
2.4.3. Method validation
The developed method was then validated to check its accuracy, precision,
robustness and rigidity. The method was validated per US FDA guidance for bioanalytical
method validation. The validation parameters evaluated were linearity, accuracy and
precision, selectivity, recovery, matrix effect, and stability.
2.4.3.1. Linearity
To ensure that the selected range is suitable for analysis, six calibration curves were
constructed in same serum matrix for each analyte. The calibration curve is the plot of the
ratio of the analyte peak area over the internal standard peak area versus the nominal
concentration. Linear regression was selected applying a weighting factor of 1/x. The FDA
guidelines state that for lower limit of quantitation LLOQ the acceptable deviation from
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the nominal concentration is < 20% and < 15% for the other calibration points and that
67% of the calibrators, including LLOQ and upper limit of quantitation ULOQ, being
within these acceptance criteria.
2.4.3.2. Accuracy, precision, and sensitivity
Five quality control (QC) samples from each level and LLOQ were run to determine
intra-day accuracy and precision. To study the inter-day accuracy and precision, five QC
samples from each level were prepared on 3 separate days and run immediately on the
instrument after preparation. Accuracy was determined by how close the mean of the intraday QC sample results were to the nominal value. The method is considered accurate if the
measured concentration is within 85%-115% (80%-120% for LLOQ) of the expected
value. The acceptable precision criterion is a coefficient of variation (CV%) of the QC
sample analyte concentration being no more than 15% (LLOQ not more than 20%).
2.4.3.3. Selectivity
A selectivity test was done to ensure that the samples were free of interference. Six
different serum batches were used to prepare blank and LLOQ samples. The LLOQ peak
height (or peak area) must be at least 5 times of any peak detected in the corresponding
blank samples at the same retention time of the analyte in order to be considered free from
interference.
2.4.3.4. Recovery
The efficiency of the extraction protocol was evaluated through the recovery test.
Three QC samples (low, mid, and high) were prepared pre- and post-extraction in triplicate.
The analyte/internal standard peak area in spiked samples before extraction over the
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analyte/internal standard peak area in spiked samples after extraction was used to calculate
the relative recovery. There is no limit for the recovery; however, the results need to be
consistent, precise and reproducible, as assessed by the coefficient of variation for each QC
sample type being no more than 15%. The CV% was calculated as CV % =
[(DX/X)2+(DY/Y)2)]1/2, where DX is the standard deviation for the pre-extraction samples,
X is the mean area ratio of pre-extraction samples, DY is the standard deviation for the
post-extraction samples, and Y is the mean area ratio of post-extraction samples.
2.4.3.5. Matrix effect
The matrix effect is the variability in analyte response due to the sample matrix. To
evaluate the matrix effect, QC low was prepared in triplicate in six different serum batches.
Matrix effect, calculated as a matrix factor percent (MF%), was calculated as follows: ratio
of peak area ratio of spiked analyte/internal standard for the QC low samples after
extraction (n=18) over the peak area ratio of the spiked analyte/internal standard in
methanol: H2O, 1:1 (n=3). CV% was calculated as described in section 2.4.3.4.
2.4.3.6. Stability
The stability test was done to ensure that the analytes were stable in solution and in
the matrix under different conditions. To study the stability in solution (methanol: H2O),
LLOQ, ULOQ, and the internal standard were prepared and kept at room temperature for
6 hours or at 4ºC for 9 days. The prepared samples were compared with freshly prepared
samples from stock stored at -20ºC. The peak area was used to compare the samples and
the test was performed in triplicate.
In many cases the analytical run will last for more than 24 hours. To ensure that the
processed samples were stable during the analytical run, post-preparative stability was
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studied by keeping 5 samples of each of the three QC levels for 43 hours at 4ºC. Six samples
of each QC low and high were used to evaluate the stability in serum under different
conditions -- keeping the samples on the bench at room temperature for 21 hours (“bench
top stability”); subjecting the samples to three freeze-thaw cycles (24 h at -80ºC with thaw
at room temperature; “freeze thaw stability”); storing the samples at -80ºC for 28 weeks
(“long-term stability”). To evaluate the stability, the concentrations in these samples were
compared to the nominal values by running freshly prepared calibration curves. The
accuracy had to fall within the 85-115% acceptance criteria and the relative standard
deviation RSD could not exceed 15%.
2.4.4. Standards and quality control (QC)
Abiraterone and its metabolites were dissolved in methanol to prepare the stock
solution of each at a concentration of 1 mg/mL. The working standard was prepared by
mixing the stock solutions in one flask and diluted using methanol:H2O at 1:1; the final
concentration of abiraterone was 5.0 µg/mL and 0.25 µg/mL for the other metabolites.
Freshly prepared working standard was used to prepare the serum calibrators and serum
QC samples, all of which contained appropriate concentrations of all the analytes. Quality
control samples were prepared at three levels, QC Low (3x LLOQ), QC Mid (half ULOQ),
and QC High, which is 80% of ULOQ. The final concentrations of the calibrators and
serum QC samples are listed in Table 1. The internal standard stock (2 mg/mL) was
prepared by dissolving the stock powder in 100% methanol and further diluting it with
methanol:H2O at 1:1 to a final concentration of 2.5 μg/mL. Stock and working standard
solutions were stored at -20°C, and the calibrators with QC samples were freshly prepared
through the validation.
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Table 1. Calibrators and quality control samples.
Sample
Calibrator 1
Calibrator 2
Calibrator 3
Calibrator 4
Calibrator 5
Calibrator 6
Calibrator 7
QC Low
QC Mid
QC High

Volume of
Working
Standard (μL)
20
40
120
300
600
1400
2000
60
1000
1600

Final
Volume
(mL)
10
10
10
5
5
5
5
10
5
5
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Final Concentration in Serum
ng/mL
Abiraterone
Metabolites
2
0.1
4
0.2
12
0.6
60
3
120
6
280
14
400
20
6
0.3
200
10
320
16

2.5.

Results and Discussion

2.5.1. Method development
The challenge in the development of a comprehensive pharmacokinetic (PK)
technique to determine parent drug and metabolites is to separate these compounds without
compromising sensitivity and linearity. The goal here was to develop an LC-MS/MS
method with an available column and reagents so the method can be adopted easily by
anyone performing the same type of stereoisomer analysis. Several mobile phases were
evaluated,

including

different

organic

modifiers

(methanol,

acetonitrile

and

methanol/acetonitrile mixtures) at various concentrations in water, as well mobile phases
containing ammonium formate and/or formic acid without organic modifier. The Prodigy
Phenomenix C18 analytical columns were also evaluated. Optimization of sample
preparation according to recovery was also performed, various volumes of MTBE, as well
as evaluating acidic and neutral reconstitution solutions. The best method was then selected
based on the separation of all metabolites as well as based on the analytical qualities of
linearity and sensitivity.
2.5.1.1. Optimization of the mass analyzer
Because of the steroidal nature of these metabolites and the presence of a pyridyl
moiety, the mass analyzer was operated with electrospray ionization in the positive mode.
The mass spectrometric parameters were optimized to ensure that the highest sensitivity
possible would be achieved. Nitrogen was used as the nebulizing (40 L/min) agent and
drying gas (30 L/min). Ion spray voltage and the source temperature were regulated at
2500 V and 500°C, respectively. All the analytes have the same declustering potential (120
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V), collision energy (60 V), entrance potential (10 V) and collision exit potential (13 V).
The metabolites mass transitions are given in Table 2.
2.5.1.2. Optimization of the chromatographic conditions
Due to the difficulty in distinguishing between the metabolites based on their MRM
transition, we separated the metabolites (as well as the parent compound) by
chromatography. Isocratic chromatographic conditions were optimized, investigating the
effect of various mobile phase components at different concentrations. Separation of drug
metabolites was achieved using a Zorbax Eclipse Plus C18 column 150 mm x 2.1 mm, 3.5
µm (Agilent, Santa Clara, CA) at 40ºC with an isocratic mobile phase consisting of 35%
A (0.1% formic acid in water) and 65% B (0.1% formic acid in methanol:acetonitrile
(60:40), at a flow rate of 0.2 mL/min. Sample injection volume was 10 μL, and analytical
run time was 13 minutes. Using the optimized chromatographic conditions resulted in
separating the parent compound and metabolites, as shown in Figure 9. It should be noted
that the method was able to resolve diastereomeric metabolites with a C18 column -- chiral
columns were not required for separation of these stereoisomers. The employment of a
methanol/acetonitrile mixture was critical to achieve this separation, as methanol or
acetonitrile as the sole organic modifier in the mobile phase did not resolve the chiral
compounds.
2.5.1.3. Optimizing the sample preparation
The metabolites were extracted from serum following liquid-liquid extraction.
Different volumes of MTBE and various reconstitution solvents to achieve higher recovery
and cleaner samples were tested. Each calibrator and QC sample was taken through the
following sample preparation steps. Serum, 100 µL, with spiked analytes was placed in a
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glass tube, and 20 µL 2.5 μg/mL internal standard working solution was added. The
samples were vortexed for 30 seconds. After addition of 2 mL MTBE, the samples were
vortexed for 1 minute. The samples were then centrifuged for 5 min at 4000 rpm at 4ºC.
The organic layer was transferred to another tube and evaporated to dryness under nitrogen
at 40ºC. 300 µL 1:1 methanol: H2O was used to reconstitute the dried extract and 200 µL
was transferred to an HPLC vial.
2.5.2. Method validation
The method was validated according to FDA guidelines. As discussed below, all
guideline criteria were met. All the analytes were stable in solution and serum, meeting
the stability criterion. The criteria for linearity, accuracy and precision fell within the
acceptance criteria. The method gave excellent recovery without matrix effects or
interference.
2.5.2.1. Linearity
To evaluate the linearity for each analyte six calibration plots were generated.
Seven non-zero points were used to generate the calibration curve. The plot of the response
ratio (analyte peak area over internal standard peak area) versus the analyte concentration
was linear. The mean values for slope, intercept and R2 values for each analyte are listed
in Table 3.
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Table 2. Mass transition of abiraterone metabolites.
Analyte

Q1 (m/z)

Q3 (m/z)

Abiraterone
D4A
3-keto-5α-Abi
3α-OH-5α-Abi
3β-OH-5α-Abi
3-keto-5β-Abi
3α-OH-5β-Abi
3β-OH-5β-Abi
Abiraterone-d4 (IS)

350.5
348.3
350.3
352.4
352.3
350.4
352.4
352.1
354.4

156.1
156.1
156.2
156.2
156.1
156.1
156.4
156.1
160.1

IS = internal standard
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Figure 9. Chromatogram for abiraterone and its metabolites. The results were obtained
by injecting 10 μL of 50 ng/mL standard solutions for A, Abi; B, D4A; C, 3-keto-5α-Abi;
D, 3α-OH-5α-Abi; E, 3β-OH-5α-Abi; F, 3-keto-5β-Abi; G, 3α-OH-5β-Abi; and H, 3βOH-5β-Abi.
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Table 3. Mean values for slope, intercept and R2
Analyte
Abiraterone
D4A
3-keto-5α-Abi
3α-OH-5α-Abi
3β-OH-5α-Abi
3-keto-5β-Abi
3α-OH-5β-Abi
3β-OH-5β-Abi

Slope
1.80E-02
2.47E-02
2.00E-02
2.16E-02
2.56E-02
1.15E-02
1.26E-02
2.03E-03
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Intercept
8.17E-03
3.00E-06
1.04E-04
-6.33E-05
1.21E-04
3.80E-05
-3.67E-05
5.00E-06

R2
0.9990
0.9996
0.9995
0.9995
0.9996
0.9995
0.9995
0.9991

2.5.2.2. Accuracy and precision
To test the method’s accuracy and precision, five replicates of each QC sample
were prepared on three different days. Five LLOQ samples were prepared in the first batch,
and the intraday accuracy mean values were 85.3-111.2 %. All the results fall within the
FDA acceptance criteria. The measured concentrations (in ng/mL) and the results for interand intra-day precision and accuracy determination are given in Table 4. Nominal
concentrations for abiraterone (LLOQ = 2, QC low = 6, mid = 200, and high = 320 ng/mL);
and the nominal concentrations for the metabolites (LLOQ = 0.1, QC low = 0.3, mid=10,
and high=16 ng/mL).
2.5.2.3. Selectivity
Testing of six LLOQ samples, each prepared from different serum batches, were
compared to their blank samples showed that the serum was free from interference. The
MRM chromatograms for the six representative blank samples compared to the MRM
chromatograms of LLOQ samples of abiraterone and its 7 steroidal metabolites are shown
in Figure 10.
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Figure 10. Representative chromatogram of selectivity studies comparing blank samples
(left chromatograms) matched to LLOQ (right chromatograms) for A, Abi; B, D4A; C, 3keto-5α-Abi; D, 3-keto-5β-Abi; E, 3α-OH-5α-Abi; F, 3α-OH-5β-Abi; G, 3β-OH-5α-Abi;
and H, 3β-OH-5β-Abi.
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Table 4. Intra- and inter-day accuracy and precision.

Analyte

Abiraterone

D4A

3-keto-5αAbi

3α-OH-5αAbi

3β-OH-5αAbi

3-keto-5βAbi

3α-OH-5βAbi

3β-OH-5βAbi

Intra-day (n=5)
Inter-day (n=15)
Measured
Accuracy RSD
Measured
Accuracy RSD
Concentration
%
% Concentration
%
%
2.05
6.4
203.8
316
0.111
0.307
10.02
16.4
0.111
0.322
10.32
16.8
0.106
0.314
9.91
14.8
0.103
0.305
9.92
16.0
0.106
0.316
9.95
15.1
0.108
0.308
9.74
15.0
0.085
0.275
9.68
14.9

102.7
106.8
102
98.7
111.2
102.3
100.2
102.3
111
107.4
103.2
104.9
106.2
104.6
99.1
92.6
103
101.5
99.2
99.9
106.4
105.4
99.5
94.2
108.4
102.6
97.4
93.8
85.3
91.7
96.8
93.3

2.89
2.65
2.06
3.86
3.89
7.76
1.86
3.02
3.43
1.56
2.86
4.68
9.23
5.96
4.41
4.97
2.63
4.21
2.07
4.63
4.13
2.56
2.7
3.61
4.26
6.74
2.98
4.65
16.8
10.7
0.99
5.6
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n.a
6.21
206.3
317
n.a
0.297
9.74
16
n.a
0.301
9.87
16.5
n.a
0.304
9.39
15.1
n.a
0.301
9.86
16.1
n.a
0.303
9.56
15.5
n.a
0.301
9.37
15.3
n.a
0.29
9.76
16

n.a
103.5
103.3
99.1
n.a
98.9
97.4
100.1
n.a
100.1
98.7
103.1
n.a
101.5
93.9
94.5
n.a
100.3
98.6
100.6
n.a
101
95.6
96.5
n.a
100.4
93.8
95.8
n.a
97.6
97.6
99.7

n.a
4.95
2.84
6.8
n.a
6.68
3.94
6.35
n.a
7.86
5.03
7.56
n.a
9.45
6.33
7.61
n.a
4.66
3.99
6.51
n.a
8.77
4.61
7.8
n.a
7.55
4.26
7.46
n.a
12.1
3.67
9.66

2.5.2.4. Recovery
The three QC levels were used to study the relative recovery, which is determined
by the percent ratio of the analyte/internal standard peak area of a spiked sample before
extraction over the analyte/internal standard peak area of a spiked sample after extraction.
The results should be consistent, precise, and reproducible. The recovery was calculated as
the mean of three triplicates for each analyte at each QC level. Recovery results and the
CV% were good and are given in Table 5. The results met the 15% CV% criterion for
acceptable recovery.
2.5.2.5. Matrix effect
The matrix effect is quantified as a matrix factor percent (MF%) by calculating the
peak area ratio of analyte/internal standard of a QC low sample (post-extraction addition
of analyte) over the peak area ratio of analyte/internal standard in a methanol/water
solution. Matrix effect results are given in Table 5, showing that the technique is
essentially free from interference.
2.5.2.6. Stability
Analytes were stable in the diluted solution stored at room temperature for 6 hours
and at 4ºC for 9 days as given in Table 6. Results of serum-based stability studies
employing QC samples are given in Table 7. The samples were found stable when stored
at the autosampler temperature at 4ºC for 43 h. The analytes were stable in serum when the
samples were left on the bench for 21 h. Even though all analytes did show a decrease in
concentration when subjected to three freeze-thaw cycles or when stored at -80ºC for 28
weeks, the results were less than 15%, which is within the criteria for accuracy.
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Table 5. Matrix effect and recovery.
MF %
Recovery %
(n=18)
(n=3)
Analyte
QC low
QC low
QC Mid
QC High
Mean RSD Mean RSD Mean RSD Mean RSD
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
Abiraterone
114.7 5.04
95.7
6.54
91.7 1.49 93.4
4.65
D4A
88.5 5.99
105.2
4.78
99.0 3.39 94.6
7.81
3-keto-5α-Abi
96.1 5.22
91.6
7.47
89.1 7.62 97.7
9.12
3α-OH-5α-Abi 92.0 5.05
91.2
7.48
85.1 4.51 95.1
5.61
3β-OH-5α-Abi 99.4 4.57
88.5
6.87
86.9 2.12 92.1
5.78
3-keto-5β-Abi
93.2 8.31
91.0
13.47 87.1 6.33 96.3
6.39
3α-OH-5β-Abi 92.0 6.74
86.0
8.47
85.1 1.09 91.1
5.64
3β-OH-5β-Abi 100.0 11.13
96.6
11.50 86.3 4.28 91.4
8.16
RSD% – relative standard deviation percent which is the same as CV%
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Table 6. Stock stability and post preparative stability.
6 Hours at RT
(n=3)
Analyte
LLOQ ULOQ
(%)
(%)
Abiraterone
98.5
103.5
D4A
100.2 102.4
3-keto-5α-Abi 112.1 103.7
3α-OH-5α-Abi 103.8 102.7
3β-OH-5α-Abi 105.2 102.1
3-keto-5β-Abi 107.6 103.7
3α-OH-5β-Abi 104.1 103.3
3β-OH-5β-Abi 115.0 104.6
RT – Room temperature

9 Days at 4⁰C
(n=3)
LLOQ ULOQ
(%)
(%)
109.5
98.4
91.1
86.9
101.6
88.4
97.9
85.7
101.7
89.3
97.5
83.2
105.0
85.4
95.4
89.7
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Post-Preparative
42 Hr (n=5)
QC
QC
QC
Low
Mid
High
97.8
101.7
98.3
96.7
96.1
100.3
100.0 100.2 101.6
103.3 100.7
102
100.0
98.7
98.1
103.3 101.7
102
100.0
96.2
97.5
103.3
98.2
100.4

Table 7. Stability in serum.

Analyte

Short-term
21 hr

Freeze- thaw
3 cycles

QC
QC
QC
Low
High
Low
Concentration
5.3
293.8
5.4
Abiraterone
Accuracy %
88.2
91.8
89.5
% RSD
6.03
1.97
11.38
Concentration
0.3
18.4
0.3
D4A
Accuracy %
100
114.8
86.7
% RSD
3.03
1.86
8.82
Concentration
0.3
15.7
0.3
3-keto-5α-Abi
Accuracy %
93.3
98.1
86.7
% RSD
8.04
2.57
12.84
Concentration
0.3
15.8
0.3
3α-OH-5α-Abi
Accuracy %
96.7
98.7
86.7
% RSD
7.16
3.4
9.82
Concentration
0.3
15.2
0.3
3β-OH-5α-Abi
Accuracy %
90
95.1
86.7
% RSD
10.28
2.22
14.55
Concentration
0.3
16.3
0.3
3-keto-5β-Abi
Accuracy %
100
101.8
93.3
% RSD
7.58
3.66
14.57
Concentration
0.3
16.1
0.3
3α-OH-5β-Abi
Accuracy %
96.7
100.8
86.7
% RSD
7.77
2.29
10.66
Concentration
0.3
16.5
0.3
3β-OH-5β-Abi
Accuracy %
93.3
103
96.7
% RSD
10.44
5.3
14.41
RSD% = relative standard deviation % is the same as CV%;
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QC
High
284.9
89
9.45
15.3
95.8
11.71
14.7
91.6
14.11
14.1
88.2
14.26
13.9
86.7
11.27
14.2
88.9
13.44
13.8
86.3
12.19
14.4
89.8
13.84

Long-term
28 weeks
QC
Low
5.7
95.5
0.82
0.3
90
3.64
0.3
86.7
5.9
0.3
86.7
7.32
0.3
86.7
4.58
0.3
86.7
4.92
0.3
90
3.65
0.3
93.3
5.21

QC
High
290.7
90.8
2.28
14.2
88.6
1.42
14.4
90.1
5.59
14.2
88.6
4.34
14.1
87.9
2.5
14.4
90.1
4.26
15
93.5
3.53
14.7
91.9
3.56

2.6.

Conclusions
In this chapter an LC-MS/MS MRM method for the determination and accurate

quantification of abiraterone and its metabolites in human serum was developed and
validated. This is the first report of a method to determine abiraterone metabolites that
result from steroidogenic metabolism. The validated LC-MS/MS method resolved and
quantitated all the metabolites despite the similarity in their structures, including resolving
diastereomers, a situation that precludes analysis of co-eluting isomers based solely on
their MRM transitions. Reversed-phase chromatographic conditions were identified to
accomplish the separation of all metabolites and their subsequent accurate quantification.
This validated method can be applied to determine abiraterone and the aforementioned
metabolites in human serum in clinical trials in which patients are treated with abiraterone
acetate.
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CHAPTER III
DETERMINATION OF ABIRATERONE METABOLITES IN VITRO AND IN
VIVO

3.1.

Development of Abiraterone
When abiraterone was first studied in 19941, it decreased circulating testosterone

levels and reduced the weights of androgen-dependent organs in mice. It was designed
based on the structure of pregnenolone, which is a substrate of CYP17A1. In the early
stages of abiraterone development, several structurally related compounds were studied
and compared with ketoconazole which was widely used as a CYP17A1 inhibitor. The 3βhydroxy, Δ5 steroidal structure with a 3 pyridyl ring at C17 and the 16, 17 double bond was
10 times more potent than ketoconazole in inhibiting CYP17A12. The 16, 17 double bond
was reported to be necessary for the irreversible inhibition of CYP17A13. The x-ray crystal
structure of CYP17A1 binding to abiraterone shows that abiraterone binds to heme iron.4
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Abiraterone was reported to inhibit 3βHSD either at high concentration or when
administered with food

5,6

. Abiraterone is administered in patients as the prodrug

abiraterone acetate (AA) in combination with prednisone 7-9.
Until recently, the main reported abiraterone metabolites were abiraterone sulfate
and N-oxide abiraterone sulfate.10 Recently, Li et al11,12 reported a new pathway of
abiraterone metabolism by steroidogenic enzymes. They studied the metabolism both in
vitro and in vivo and were able to identify seven steroidal metabolites that were generated
from abiraterone13. They studied the effect of the generated metabolites and showed that
some of the abiraterone steroidal metabolites are biochemically active and had a crucial
function in prostate cancer.
3.2.

Experimental Section

3.2.1. Materials
Iscove’s Modified Dulbecco’s (IMDM), Roswell Park Memorial Institute (RPMI)
1640 and Dulbecco’s Modified Eagle’s (DMEM) media were all purchased from (SigmaAldrich, St. Louis, MO). Fetal Bovine Serum (FBS) from Gemini (West Sacramento, CA).
VCaP cells were purchased from the American Type Culture Collection (Manassas, VA).
C4-2 cells were kindly provided by Dr. Leland Chung (Cedars-Sinai Medical Center, Los
Angeles, CA) and maintained in RPMI-1640 with 10% FBS. The LAPC4 cell line was
kindly provided by Dr. Charles Sawyers (Memorial Sloan Kettering Cancer Center, New
York, NY) and grown in IMDM with 10% FBS. All experiments done with VCaP cells
were done in plates coated with poly-DL-ornithine (Sigma-Aldrich, St. Louis, MO). Cell
lines were authenticated by DDC Medical (Fairfield, OH) and determined to be
mycoplasma-free

with

primers

5’-ACACCATGGGAGCTGGTAAT-3’
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and

5’-

GTTCATCGACTTTCAGACCCAAGGCAT3’. All reagents used to run the LC-MS are
listed in section 2.4.1.
3.2.2. In vitro metabolism of abiraterone
To test the hypothesis that steroidogenic enzymes present in prostate cancer cell
lines can convert abiraterone to its steroidal metabolites, LC-MS analyses were performed
to analyze samples obtained from in vitro assays using prostate cancer cell lines with
known enzymatic activity: C4-2 with high 3βHSD enzymatic activity and VCaP and
LAPC4 which have a robust SRD5A1 activity and a low 3βHSD enzymatic activity. Cells
were seeded and incubated in 12-well plates with 0.2 million cells/well for ~24 h and then
incubated with 1µM of abiraterone, D4A, 3-keto-5α-Abi, 3α-OH-5α-Abi, 3β-OH-5α-Abi,
3-keto-5β-Abi, 3α-OH-5β-Abi or 3β-OH-5β-Abi, for 24 and 48 hr. Media was collected at
the two time points and were subjected to LC-MS analysis. This experiment was performed
in triplicate for each drug and was repeated for three biological repeats.
3.2.3. Abiraterone metabolism in mice
To confirm that abiraterone is metabolized by steroidogenic enzymes, LC-MS
analysis was utilized to confirm the metabolism in mice. Male NSG mice, 6 to 8 weeks of
age were obtained from the Cleveland Clinic Biological Resources Unit facility. All mouse
studies were conducted under a protocol approved by the Cleveland Clinic Institutional
Animal Care and Use Committee. Mice were injected intraperitoneally with 100 µL
solution containing 0.15 mmol/kg of either abiraterone (n=5), D4A (n=5), 3-keto-5α-Abi
(n=4), 3α-OH-5α-Abi (n=4), or 3β-OH-5α-Abi (n = 4 mice/group). Blood was collected 2
and 4 hrs after injection, centrifuged at 10,000 rpm, and the sera were stored at -80ºC for
LC-MS analysis.
56

3.2.4. Pharmacokinetics of abiraterone and its steroidal metabolites in human
The activities conferred by steroidal metabolites of abiraterone may make them
biomarkers of clinical response or treatment resistance. To study the pharmacokinetics
(PK) of abiraterone and its seven steroidal metabolites in humans, plasma samples from a
clinical trial led by Janssen Pharmaceuticals were analyzed. In this pharmacokinetics study,
15 healthy male volunteers received a single oral dose of 1000 mg abiraterone acetate plus
240 mg of the AR antagonist apalutamide under fasting conditions. Serial plasma samples
were collected from each volunteer to cover the period from 0-96 hours post-dose as
follows: pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, and 96 hours. Aliquots of the plasma
samples were subjected to LC-MS analysis to quantify the concentrations of abiraterone
and its seven structurally related steroidal metabolites and to assess the pharmacokinetics
parameters for each of the metabolites.
3.2.5. LC-MS analysis
All samples collected from cell metabolism, mouse metabolism, and the
pharmacokinetics studies were subjected to LC-MS analysis. All the analyses were
performed using the same mass spectrometer conditions and chromatographic conditions;
the only difference was the sample preparation procedure. The cell metabolism sample
preparation was as follows: To 200 µL media 40 µL internal standard (abiraterone-d4) was
added and then the analytes were extracted with 2 ml TMBE, the TMBE was evaporated,
and the remaining sample was reconstituted with 200 µL methanol:H2O; 1:1. The standard
curves were prepared in media. Samples obtained from mice were subjected to direct
protein precipitation as follows: To 20 µL mouse serum, 180 µL methanol containing the
IS was added; the sample was centrifuged at 10,000 g for 10 min, and then 120 µL
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supernatant was transferred to HPLC vials. The standard curves were prepared in drug-free
mouse sera. The pharmacokinetic samples were prepared as follows: 100 µL of human
plasma was spiked with 20 µL IS, 2 ml of TBME was added, the samples were then
vortexed and centrifuged. The organic layer was evaporated and the samples were
reconstituted with 300 µL methanol:H2O; 1:1.
3.3.

Results and Discussion

3.3.1. Cell metabolism
3βHSD enzymatic activity is present in the C4-2 cell line; therefore treating the
cells with abiraterone resulted in detection of the abiraterone downstream metabolites as
shown in Figure 11A. When the cells were treated with D4A, the downstream metabolites
also were detected but not abiraterone itself (Fig 11B). This indicates that 3βHSD activity
is not reversible and D4A was fully consumed and metabolized after 48 hours. Treating
the cells with any of the 5α-reduced metabolites resulted in detecting the other two 5αreduced metabolites (Fig. 11C-E). This behavior was not observed with 5β-reduced
metabolite. Only when the cells were treated with 3-keto-5β-Abi all three 5β reduced
metabolites were detected (Fig. 11F). However, treating the cells with either 3α-OH-5βAbi or 3β-OH-5β-Abi did not result in detecting all 5β-reduced metabolites (Fig. 11G&H).
In the C4-2 cell line as well as VCaP and LAPC4 cells, 5β-reductase enzymatic activity is
absent. Therefore, only 5α-reduced metabolites were detected when cells were treated with
abiraterone or D4A. In contrast to C4-2, LAPC4 and VCaP cell line have low 3βHSD
activity. Therefore, treating the cells with abiraterone resulted in low yield of the
downstream metabolites (Fig. 12A &13A). D4A treatment in the two cell lines resulted in
high yield of the 5α-reduced metabolites which substantiates their robust SRD5A1 activity

58

(Fig. 12B &13B). In VCaP and LAPC4 cells, the conversion of the 5α reduced metabolites
was not interchangeable (Fig. 12C-E &13C-E) due to low 3βHSD activity, which is
responsible for converting 3β-OH-5α-Abi back to 3-keto-5α-Abi. 3-keto-5β-Abi
conversion was fast, with only 20% and 30% of the metabolites left in the media after 24
hours and almost nothing left after 48 hours (Fig. 12F&13F). Treating the cells with 3αOH-5β-Abi did not result in detecting any of the other 5β-reduced metabolites (Fig
12G&13G). In VCaP cells within 24 hours, 20% of 3β-OH-5β-Abi was converted to 3αOH-5β-Abi. However, in LAPC4 cells it took 48 hours to reach this percentage (Fig
12H&13H). Together all these results suggest that steroidogenic enzymes are responsible
for the metabolism and formation of abiraterone steroidal metabolites and that once the
metabolites are formed, they cannot be converted back to abiraterone.
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Figure 11. Metabolism of abiraterone and its metabolites in C4-2 cells. A, Abi; B, D4A;
C, 3-keto-5α-Abi; D, 3α-OH-5α-Abi; E, 3β-OH-5α-Abi; F, 3-keto-5β-Abi; G, 3α-OH-5βAbi; and H, 3β-OH-5β-Abi.
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Figure 12. Metabolism of abiraterone and its metabolites in VCaP cells. A, Abi; B, D4A;
C, 3-keto-5α-Abi; D, 3α-OH-5α-Abi; E, 3β-OH-5α-Abi; F, 3-keto-5β-Abi; G, 3α-OH-5βAbi; and H, 3β-OH-5β-Abi.
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Figure 13. Metabolism of abiraterone and its metabolites in LAPC4 cells. A, Abi; B,
D4A; C, 3-keto-5α-Abi; D, 3α-OH-5α-Abi; E, 3β-OH-5α-Abi; F, 3-keto-5β-Abi; G, 3αOH-5β-Abi; and H, 3β-OH-5β-Abi.
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3.3.2. Abiraterone in vivo metabolism
To confirm that the metabolism occurs in mice, a PK experiment was performed.
Blood samples were collected 2 and 4 hr after the metabolite injection into NSG mice. The
LC-MS analysis of mouse sera showed that abiraterone metabolism was fast: by 2 hrs after
abiraterone injection, more than 40% was converted to the downstream metabolites,
including the 5β-reduced metabolites (Fig 14A). In contrast, in the group of mice injected
with D4A, the metabolism of D4A was not fast: only 20% was converted to the downstream
metabolites after 4 hrs (Fig 14B). This could be due to the inhibitory effect of D4A on
steroidogenic enzymes. Similar to the cell lines, conversion of the three 5α-reduced
metabolites is reversible; injecting any of the 5α-reduced metabolites resulted in detecting
all three of them but not abiraterone, D4A, or any of the 5β-reduced metabolites (Fig 14CE). The favorite reduction pathway for 3-keto-5α-Abi is through 3α-HSD to produce 3αOH-5α-Abi, as 45% of 3-keto-5α-Abi was converted (Fig 14C). In the other hand, the
reversible reaction was slow: less than 10% of 3α-OH-5α-Abi was converted to 3-keto-5αAbi. However, the 3β-OH-5α-Abi metabolite when injected into the mice resulted in the
formation of both 3-keto-5α-Abi and 3α-OH-5α-Abi. All these results suggest that
abiraterone metabolism occurs fast in mice and that none of the metabolites can generate
abiraterone.
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Figure 14. In vivo metabolism of abiraterone and its metabolites in NSG mice. A, Abi; B,
D4A; C, 3-keto-5α-Abi; D, 3α-OH-5α-Abi; E, 3β-OH-5α-Abi.
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3.3.3. Pharmacokinetics studies in humans
Abiraterone bioavailability was reported to be highly variable14. However, little is
known about steroidal metabolites of abiraterone regarding the temporal nature of their
formation and elimination that would inform the timing of metabolite sampling for
biomarker studies. Analysis of pharmacokinetics samples from 15 healthy volunteers
confirmed that not just abiraterone but its metabolites were also variable.

All the

metabolites were detected in the volunteers. The results in Figure 15A-H show the
variability of the metabolite concentrations in the volunteers. The drop in the mean
percentage of abiraterone over time is accompanied by a rise in the 5β-reduced metabolites
(Fig 16). The pharmacokinetics analysis was performed assuming a non-compartmental
model. The metabolite maximum concentration was achieved between 1.9-19.3 hours. The
mean Tmax was 1.9 hr for abiraterone, 2.1 hr for D4A, and 2.7 hr for 3-keto-5α-Abi, and
ranged between 3.2 and 19.3 hrs for the other metabolites (Table 8). The mean Cmax was
90 ng/ml for abiraterone, 0.91 ng/ml for D4A, and 5.5 ng/ml for 3-keto-5α-Abi (Table 9).
The mean AUC at 96 hrs ranged from 5.0 for 3β-OH-5α-Abi to 504 for abiraterone (Table
10). These data suggest that abiraterone metabolism via steroidogenic enzymes takes place
rapidly and that D4A and 3-keto-5α-Abi are generated in rapid succession from the first
abiraterone dose. This is the first study to evaluate the pharmacokinetics parameters of
abiraterone and its seven steroidal metabolites in healthy volunteers, and these data will
help in designing biomarker studies of abiraterone metabolite levels to enhance clinical
treatment.
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Figure 15. Pharmacokinetics of abiraterone metabolites in human serum. 15 healthy
individual (color coded) draw blood up to 96 h after single dose of abiraterone acetate. A,
Abi; B, D4A; C, 3-keto-5α-Abi; D, 3α-OH-5α-Abi; E, 3β-OH-5α-Abi; F, 3-keto-5β-Abi;
G, 3α-OH-5β-Abi; and H, 3β-OH-5β-Abi.
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Figure 16. The mean percentage of abiraterone metabolites in human serum at 12 time
points to cover the period (0.5-96 h)
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Table 8. Tmax (hours) for abiraterone metabolites.
Analyte

Min

25th
Percentile

Median

75th
Percentile

Abiraterone

1.0

1.5

1.5

2.0

4.0

1.9

0.23

D4A

1.0

1.5

2.0

2.0

4.0

2.1

0.22

3-keto-5α-Abi

1.5

2.0

2.0

4.0

4.0

2.7

0.28

3α-OH-5α-Abi

4.0

4.0

4.0

6.0

8.0

5.1

0.38

3β-OH-5α-Abi

0

4.0

4.0

4.0

6.0

3.7

0.33

3-keto-5β-Abi

1.5

1.5

2.0

4.0

12

3.2

0.72

3α-OH-5β-Abi

2.0

4.0

8.0

24

72

19.3

5.46

3β-OH-5β-Abi

6.0

8.0

12

24

48

16.8

2.92
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Max Mean

SEM

Table 9. Cmax (ng/ml) for abiraterone metabolites.
Analyte

Min

25th
Percentile

Median

75th
Percentile

Max

Mean

SEM

Abiraterone

33.8

38.3

65.5

116.7

223.3

90.1

15.2

D4A

0.43

0.57

0.81

1.31

2.12

0.91

0.12

3-keto-5α-Abi

1.18

2.76

4.59

6.72

22.6

5.54

1.33

3α-OH-5α-Abi

0.16

0.44

0.76

1.47

4.07

1.06

0.25

3β-OH-5α-Abi

0.00

0.15

0.23

0.49

1.84

0.39

0.11

3-keto-5β-Abi

0.63

1.13

1.32

1.85

3.53

1.51

0.18

3α-OH-5β-Abi

0.44

0.90

1.19

1.77

3.02

1.41

0.18

3β-OH-5β-Abi

0.91

2.58

3.14

6.91

10.5

4.55

0.75
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Table 10. AUC at 96 hours for abiraterone metabolites.
Analyte

Min

25th
Percentile

Median

75th
Percentile

Abiraterone

165

233

322

596

1784

504

110

D4A

2.59

6.21

8.83

10.5

18.7

8.86

1.14

3-keto-5α-Abi

9.46

25.7

40.4

54.7

235

52.7

13.85

3α-OH-5α-Abi

1.99

4.98

8.81

16.8

63.4

14.3

3.88

3β-OH-5α-Abi

0.00

0.75

1.51

5.87

31.5

5.04

2.10

3-keto-5β-Abi

1.69

14.0

19.7

41.6

57.9

27.0

4.45

3α-OH-5β-Abi

20.1

44.2

52.1

103

162

70.6

10.21

3β-OH-5β-Abi

22.8

99.3

128

320

455

188

34.77
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Max Mean

SEM

3.4.

Conclusion
Until recently, very little was known about steroidogenic metabolism of

abiraterone. The work presented here demonstrates that steroidogenic enzymes metabolize
abiraterone to at least seven new compounds. The formation of the metabolites was fast as
confirmed by in vitro and in vivo experiments. Conversion of abiraterone and D4A to
downstream metabolites was irreversible. This was confirmed by showing that the
accumulation of products did not drive flux to their precursors (in this case abiraterone and
D4A). In healthy human subjects, the metabolism was also fast, and all the metabolites
were detected from the first dose of abiraterone acetate. All these data confirmed the
presence of a previously unappreciated novel pathway of abiraterone metabolism.
3.5.
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CHAPTER IV
ABIRATERONE METABOLISM IN PATIENTS WITH CASTRATIONRESISTANT PROSTATE CANCER

4.1.

Background
Prior to its approval in 2011, abiraterone acetate went through several clinical trials

to evaluate its efficacy, safety, and the dose. The first study, which was three small clinical
trials, was reported in 2004 1. In these trials the major objective was to determine the dose
that will result in maximum suppression of testosterone; the other objectives include safety
and tolerability, pharmacokinetics, and evaluating some endocrine data. The second
clinical trial was reported in 2008 2; it was a phase I/II clinical study with escalating dose
of abiraterone acetate to evaluate drug safety, pharmacokinetics, and activity in
chemotherapy-naive patients with CRPC. Based on the outcomes of this study, the selected
dose for treatment in clinical practice was 1000 mg daily. The major side effects were
associated with the blockade of CYP17A1 activity; which lowers glucocorticoid and
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elevates mineralocorticoid levels. The side effects included hypertension, hypokalemia,
and fluid retention, which were managed with a mineralocorticoid antagonist, and can be
prevented when abiraterone acetate is administered with prednisone. Other clinical trials
evaluated abiraterone acetate after ketoconazole3 or in patients with prior treatment with
chemotherapy4,5. Phase III trials were double-blind, placebo-controlled, multicenter
designs for patients with prior chemotherapy (COU-AA-301)6 or chemotherapy-naive
CRPC patients (COU-AA-302) 7. Based on the outcome of these two clinical trials for
CRPC treatment, the US FDA approved abiraterone acetate in combination with
prednisone to treat CRPC patients before or after chemotherapy. Since its approval,
updated trial results have been published -- the median overall survival was 15.2 in
abiraterone acetate plus prednisone arm, compared to 11.8 in the placebo plus prednisone
arm for (COU-AA-301)8. Median overall survival was 34.7 months in the abiraterone
group vs 30.3 months in the control group (COU-AA-302)9.
As discussed in Chapter 3, abiraterone metabolism in vitro and in vivo generated at
least seven metabolites through steroidogenic enzyme activity. The metabolites were also
present in healthy humans in a clinical trial to evaluate the PK parameters after single dose
of abiraterone acetate. Abiraterone metabolites play an important role in prostate cancer.
D4A is the first downstream metabolite and inhibits the following steroidogenic enzymes:
CYP17A1, 3βHSD1, and SRD5A1. It also inhibits expression of the AR-responsive genes:
prostate-specific antigen (PSA), TMPRSS2, and FKBP5. In vivo, D4A inhibits tumor
progression in xenograft mice when compared to abiraterone acetate10. However further
metabolism of D4A will not only result in losing its effect, it will generate 3-keto-5α-Abi
which stimulates the expression of AR-responsive genes and promotes tumor progression
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in xenograft mice11. Thus, it was important to determine the metabolite levels in patients
treated with abiraterone acetate.
This chapter focuses on determining abiraterone metabolites in several clinical
trials that included investigation of the effect increasing the frequency of abiraterone
acetate dose or adding steroidogenic enzyme inhibitors on abiraterone metabolism. In the
first trial CRPC patients received a standard dose of abiraterone acetate (1 gm daily) with
5 mg twice daily of prednisone (a drug administered with abiraterone acetate to overcome
adverse events). In the second study, 1 gm daily of abiraterone acetate was combined with
leuprolide acetate (an LHRH agonist)12. The third study combined abiraterone acetate with
prednisone and dutasteride (a SRD5A1 inhibitor that is used to treat benign prostate
hyperplasia)13. The fourth and last trial was designed to study the effect of increasing the
abiraterone acetate dose from 1 gm daily to 1 gm twice daily. Samples from the four trials
were obtained and subjected to LC-MS analysis to measure the metabolite levels.
4.2.

Determination of Abiraterone Metabolism in Clinical Trials
The common aim of these trials was to maximize the benefit of abiraterone

treatment. None of these trials had a major objective to study abiraterone metabolism;
however, one of the approaches to achieve the goals of these trials was through determining
abiraterone metabolites and correlating them with clinical outcomes.
4.2.1. CRPC patients treated with standard dose of abiraterone acetate
In a clinical study held at the Cleveland Clinic under an Institutional Review Board
– approved protocol (Case 7813), CRPC patients received a standard dose of abiraterone
acetate (1gm daily) and 5mg twice daily of prednisone on an outpatient basis. The primary
objective of this research study was to identify the biochemical mechanisms that underlie
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resistance to hormonal therapies in advanced prostate cancer and to define the underlying
mechanisms. One of the approaches was to determine abiraterone metabolites in the sera
of the patients and correlate the levels with the clinical outcomes. The time from the daily
dose to the blood draw was recorded. Blood was collected using Vacutainer Plus serum
blood collection tubes (#BD367814, Becton Dickenson, Franklin Lakes, NJ). Blood was
collected between 1 and 16 hours after the daily dose of abiraterone acetate was
administered. Blood was allowed to clot and tubes were centrifuged at 2500 rpm for 10
minutes. Serum aliquots were frozen at -80°C until processing.
4.2.2. Neoadjuvant study of abiraterone in combination with an LHRH agonist
This clinical trial (NCT00924469) was a phase II open-label, randomized, multicenter study of neoadjuvant abiraterone acetate plus leuprolide acetate (an LHRH agonist)
and prednisone versus leuprolide acetate alone in men with localized high-risk prostate
cancer performed at Dana Farber Cancer Institute; and all patients provided written
informed consent. The patients received the treatment for 24 weeks and then underwent
surgery (prostatectomy). On the day of surgery, a blood sample also was drawn. The major
aim of this trial was to evaluate the safety and efficacy of the combined treatment.
However, for the purpose of this research, abiraterone and the metabolite levels were
compared in both the prostate tissue and serum and were correlated with the clinical
outcome.
4.2.3. Effect of increasing frequency to abiraterone acetate
This was a single arm, open–label, multicenter, phase II study conducted at the
University of California San Francisco UCSF and Oregon Health and Science University
OHSU. The study was approved by UCSF and OHSU Institutional Review Boards and all
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patients provided written informed consent prior to participation. The trial aim was to
evaluate the efficacy and safety of increasing abiraterone acetate dose in chemotherapynaïve CRPC patients3. All patients started with the standard dose of abiraterone acetate and
prednisone until the PSA concentration increased by 25% above nadir or until clinical or
radiographic progression. At the time of disease progression, abiraterone acetate dose was
increased to 1gm twice daily, and patients were monitored for a minimum of 12 weeks or
until subsequent PSA, radiographic, or clinical progression.
4.2.4. Combining dutasteride with abiraterone acetate
This was a phase II, single-arm, multi-center, open-label study (NCT01393730)
performed at Dana Farber Cancer Institute; all patients provided written informed consent.
The main purpose of this research study was to determine the efficacy of adding dutasteride
(SRD5A1 inhibitor) to abiraterone acetate and prednisone in patients with CRPC. Our
purpose was to determine whether adding dutasteride would alter abiraterone metabolism
by blocking D4A metabolism to the 5α-reduced metabolites, which may increase the levels
of D4A and abiraterone, thus may be correlated with the clinical outcomes. Patients were
treated with abiraterone acetate (1gm daily) and prednisone (5 mg daily) for two 4-week
cycles. After this time, high-dose dutasteride (3.5 mg daily) was added (start of cycle 3).
Patients continued on the 3-drug regimen until study withdrawal or radiographic disease
progression. Blood samples were available from beginning of cycle 3, cycle 4, and cycle
7.
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4.3.

Results and Discussion

4.3.1. CRPC patients receiving standard dose of abiraterone acetate
This study is still recruiting patients in an ongoing basis. The patients included in
the analysis were diagnosed with prostate cancer between January, 1994 and May, 2014
and began treatment with abiraterone acetate between December, 2011 and May, 2015.
Samples from 34 patients were available for LC-MS analysis. All seven abiraterone
metabolites were detected despite the treatment duration or time to blood draw (Table 11).
Abiraterone as a percentage of the total metabolites was the greatest compared to all other
metabolites, with a mean value of 43%. The lowest metabolite percentage was 3β-OH-5αAbi at only 0.69% of the total metabolites. D4A has been reported to be more potent than
abiraterone in inhibiting AR regulated gene expression. D4A levels never exceeded that of
abiraterone in patients; the ratio of D4A: abiraterone ranged from 0.03-0.36 with a mean
of 0.07. On the other hand, the ratio of 3-keto-5α-Abi:D4A ranged from 0.84-12.94 with a
mean of 3.73. PSA concentration and HSD3B1genotype (a gene that can be mutated in
CRPC patients) were evaluated for any correlation with the metabolite levels. However,
due to the limited number of patients with a mutated gene (n=3) it was difficult to find
correlations between the metabolite levels with the genotype and clinical outcomes.
4.3.2. Neoadjuvant study of abiraterone in combination with an LHRH agonist
Patients were enrolled from September 2009 through June 2011. Patients were
randomized to treatment with abiraterone in combination with leuprolide and prednisone
or leuprolide alone for 12 weeks. Then all patients received another 12 weeks of
combination abiraterone, leuprolide and prednisone. After 24 weeks of neoadjuvant
therapy, patients underwent surgery (prostatectomy). Abiraterone and leuprolide were able
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to suppress tissue androgens more effectively compared to leuprolide alone. Samples from
15 patients were available for LC-MS analysis. Abiraterone metabolites were detected in
both tissue and serum. In general, abiraterone levels in serum were lower than in tissue
when calculated as percentage of all metabolites (Fig 17A). SRD5A activity is high in the
prostate; thus, the D4A percentage was higher in serum than in the prostate (Fig 17B).
Among all 5-reduced metabolites (Fig 17C-H), 3β-OH-5α-abi has higher tissue levels. For
no metabolite did the concentration correlate with androgen levels in tissue or serum.
However, the percentage of 3α-OH-5β-Abi and 3β-OH-5β-Abi in tissue and abiraterone in
serum were correlated with baseline serum PSA when calculated using the Kruskal-Wallis
test (Table 12).
4.3.3. Effect of increasing frequency to abiraterone acetate
Forty-one patients enrolled in the study from March 2013 to March 2014. In 14 of
the 41 patients, the abiraterone dose was increased to 1 gm twice daily. When compared
with the standard abiraterone acetate dose, abiraterone levels increased in 10 patients (Fig
18A), D4A levels increased in 8 (Fig 18B). Similar to abiraterone, 3-keto-5α-Abi levels
increased in 10 patients (Fig 18C). 3α-OH-5α-Abi, 3β-OH-5α-Abi, and 3β-OH-5α-Abi had
an increased levels in 9 patients (Fig 18D,E&G). 3-keto-5β-Abi and 3β-OH-5β-Abi
increased in 12 of 14 patients (Fig. 18F&H). Overall, a non-significant increase in median
abiraterone metabolite levels was observed in patients taking the increased dose, from 13.6
ng/mL at the time of progression on the standard daily abiraterone dose to 16.2 ng/mL on
the increased dose (Table 13). Despite the escalated abiraterone dose, none of the patients
had a 30% decline in PSA at study end.
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Table 11. Concentration ng/ml of abiraterone metabolites in CRPC patients
Patient
#

Time
point
hour, min

Abi

D4A

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34

1,20
2,00
2,00
2,15
2,15
2,30
3,15
3,15
4,16
4,49
4,50
6,20
6,40
7,30
8,08
8,10
8,11
9,00
9,20
10,25
10,40
10,45
11,15
11,40
11,50
11,50
12,10
12,15
12,15
12,20
13,20
13,05
14,08
15,45

15.75
8.64
89.88
39.98
40.49
48.45
2.19
213.4
9.28
13.96
81.90
111.4
43.41
21.50
61.47
16.68
16.71
24.30
10.75
60.64
35.88
19.24
68.76
49.87
33.53
67.98
41.22
19.06
52.41
38.32
46.60
22.59
31.48
66.69

0.96
1.28
2.52
1.28
2.05
1.29
0.29
7.19
3.30
0.77
4.11
5.04
3.67
1.29
4.54
2.78
1.25
1.61
0.44
2.49
1.82
0.52
5.35
4.00
2.08
3.59
3.71
1.14
3.17
2.16
2.33
2.41
3.07
2.83

3αOH5αAbi
1.77
0.42
2.07
0.23
1.30
1.16
0.22
3.00
0.61
0.48
1.13
8.09
5.87
0.26
1.73
0.88
1.93
0.43
0.24
2.82
3.69
0.37
3.27
2.22
1.08
1.11
2.27
1.21
2.83
1.26
2.95
0.72
6.42
2.88

3keto5αAbi
6.99
1.36
10.84
3.46
9.07
10.66
0.58
28.63
2.84
2.25
6.73
65.22
20.48
1.04
9.88
3.64
8.10
1.57
0.87
10.96
12.46
1.22
15.04
11.74
4.57
5.36
11.04
4.66
10.89
7.59
15.07
4.43
20.28
8.71
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3βOH5αAbi
0.58
0.12
2.12
0.11
0.39
0.52
0.08
0.97
0.14
0.16
0.40
1.77
4.14
0.12
0.60
0.35
0.45
0.20
0.10
0.78
0.99
0.15
1.14
0.93
0.32
0.44
0.77
0.34
0.88
0.51
1.02
0.27
1.99
0.88

3keto5βAbi
7.08
2.43
21.97
6.46
4.37
5.95
0.91
45.34
20.22
2.50
21.74
46.64
12.74
4.48
14.77
18.59
8.08
10.80
0.64
7.15
5.98
1.28
17.17
15.29
3.77
16.54
25.76
11.54
8.97
9.12
23.00
5.79
7.89
4.29

3αOH5βAbi
10.19
6.46
32.81
2.04
4.90
3.44
3.15
16.90
21.29
3.98
22.28
21.05
22.04
5.52
11.85
26.08
9.84
15.83
2.02
11.11
10.52
3.83
18.59
11.25
4.13
12.53
21.59
10.95
10.57
6.13
16.96
5.47
19.94
10.53

3βOH5βAbi
22.54
9.42
41.56
3.08
5.71
6.86
1.50
34.94
33.20
6.75
19.10
27.82
19.06
12.54
24.32
28.06
15.19
16.22
2.41
10.76
16.37
4.33
24.81
21.34
4.32
27.29
37.91
12.50
19.10
10.10
31.13
6.16
15.87
12.34

Table 12. Correlation between tissue and serum metabolites with baseline PSA

Analyte
Abiraterone
D4A
3-keto-5α-Abi
3α-OH-5α-Abi
3β-OH-5α-Abi
3-keto-5β-Abi
3α-OH-5β-Abi
3β-OH-5β-Abi

Tissue vs
Baseline Serum
PSA
Coef
P
-0.56*
0.03
0.41
0.13
0.43
0.11
0.28
0.31
0.16
0.57
0.41
0.13
0.54
0.038
0.53
0.043

Serum vs
Baseline Serum
PSA
Coef
P
-0.56
0.03
0.41
0.13
-0.01
0.96
-0.09
0.74
-0.05
0.87
-0.03
0.92
-0.09
0.75
0.09
0.75

*A negative coefficient indicates the values between metabolites and PSA were inversely correlated

82

Figure 17. Abiraterone metabolites in human prostate and serum. A, Abi; B, D4A; C, 3keto-5α-Abi; D, 3α-OH-5α-Abi; E, 3β-OH-5α-Abi; F, 3-keto-5β-Abi; G, 3α-OH-5β-Abi;
and H, 3β-OH-5β-Abi.
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Figure 18. Metabolite concentration (ng/ml) after 1gm once vs. twice daily of abiraterone
acetate. A, Abi; B, D4A; C, 3-keto-5α-Abi; D, 3α-OH-5α-Abi; E, 3β-OH-5α-Abi; F, 3keto-5β-Abi; G, 3α-OH-5β-Abi; and H, 3β-OH-5β-Abi.

84

Table 13. Abiraterone dose dependent concentrations

Analyte

1gm/daily

1gm twice/daily

P

Abiraterone
D4A
3-keto-5α-Abi
3α-OH-5α-Abi
3β-OH-5α-Abi
3-keto-5β-Abi
3α-OH-5β-Abi
3β-OH-5β-Abi

13.57
1.36
4.69
1.04
0.36
3.55
7.19
15.14

16.21
1.53
6.45
1.33
0.42
6.62
9.05
18.12

0.25
0.24
0.29
0.37
0.76
0.12
0.25
0.21
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4.3.4. Effect of adding dutasteride
Based on the analysis of the clinical trial with standard abiraterone acetate dose,
(section 4.3.1.) 3-keto-5α-Abi:D4A ratio was 3.73. To test whether adding a SRD5A
inhibitor will lower this ratio, samples from the clinical trial (NCT01393730) were
analyzed. Patients enrolled between September 2011 and October 2012. Sixteen patients
who had blood collected on abiraterone acetate alone (start of cycle 3) and after the addition
of dutasteride (start of cycles 4 and 7) were included in the analysis (Fig 19A). Adding
dutasteride doubled the mean concentrations of abiraterone and D4A (191.2 nM vs.372.4
nM and 9.9 nM vs. 18.2 nM ; respectively (Table 14 and Fig 19B&C).
On the other hand, adding dutasteride resulted in a dramatic decline in the 5αreduced metabolites: 89% decline in the mean concentration of 3-keto-5α-Abi, 92% for 3αOH-5α-Abi, and 73% for 3β-OH-5α-Abi (Table 14 and Fig. 19D). Concentrations of
abiraterone, D4A, and 5α-Abi metabolites at cycle 7, the second time point after addition
of dutasteride, were similar to cycle 4 (Table 14). Finally, the addition of dutasteride, did
not decrease any of the 3 5β-reduced abiraterone metabolites, supporting a very specific
biochemical effect of SRD5A inhibition on 5α-Abi metabolism (Fig 19E). The significance
of adding dutasteride was evaluated between cycle 3 and 4 using a paired two-tailed t-test
(Table 14). Together, these findings demonstrate that the elevated ratio of 5α-Abi:D4A
in standard therapy can be lowered with dutasteride.
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Figure 19. Effect of adding dutasteride to abiraterone; clinical trial (NCT01393730). A,
Study design; B, Abi; C, D4A; D, 5α-reduced metabolites; E, 5β-reduced metabolites.
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Table 14. Effect of dutasteride on abiraterone metabolites concentrations (nM)
Analyte
Abiraterone
D4A
3-keto-5α-Abi
3α-OH-5α-Abi
3β-OH-5α-Abi
3-keto-5β-Abi
3α-OH-5β-Abi
3β-OH-5β-Abi

Cycle
3
191.20
9.94
25.76
6.09
2.69
38.74
47.78
74.05

Cycle
4
372.40
18.18
2.94
0.50
0.73
49.94
48.00
69.51

P value Cycle 3 vs Cycle 4
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Cycle
4
305.40
17.85
4.42
0.80
1.25
60.29
56.59
91.43

P
0.051
0.002
<0.0001
<0.0001
<0.0001
0.11
0.97
0.64

4.4.

Conclusion
Abiraterone was approved in 2012 based on the outcome of the clinical trial where

it showed an increase in overall survival. Since then, improving the drug is an ongoing
aim for many researchers. Although the clinical trials described in this chapter were not
designed to study abiraterone metabolites, we were able to detect abiraterone metabolites
in order to determine whether the levels of the metabolites can be used as a potential
biomarker and be correlated with clinical outcomes. None of the studies gave a clear
correlation between the metabolite levels and the clinical outcomes but this is something
that researchers need to take into consideration in future designs. In the abiraterone plus
LHRH agonist leuprolide (neoadjuvant) study, the 5α-reduced metabolites were present in
serum and the tissue at higher levels than D4A. The increased dose of abiraterone did
lower PSA but it did not achieve the study goal of a 50% decline, and although the
increased dose also raised the D4A level, the ratio D4A:3-Keto-5α-Abi remained the same.
However, combining abiraterone acetate with dutasteride can reverse the ratio by leading
to higher D4A.
4.5.
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CHAPTER V
BIOCHEMICAL ACTIVITIES OF GALETERONE STEROIDAL
METABOLITES

5.1.

Introduction
In an effort to overcome drug resistance in prostate cancer, several approaches were

taken into consideration when designing new agents, specifically, targeting androgen
biosynthesis by inhibiting steroidogenic enzymes or direct targeting and antagonizing the
AR. Abiraterone and enzalutamide are FDA-approved for treatment of CRPC. Abiraterone
inhibits the enzyme 17α-hydroxylase/17,20-lyase (CYP17A1)

1,2

, whereas enzalutamide

directly antagonizes the AR3,4. Unfortunately, tumor resistance eventually develops against
both of these agents and some evidence suggests that resistance to abiraterone is yet again
engendered by a reinstatement of AR signaling5,6
Currently under clinical development, galeterone (Gal), 17-(1H-benzimidazol-1yl) androsta-5,16-dien-3β-ol, is a steroidal 17-azole compound that inhibits CYP17A1,
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directly competes with androgens to bind and antagonize AR, promotes AR protein
degradation, and had clinical activity in a phase I/II clinical trial7-11. Galeterone shares its
Δ5, 3β-hydroxyl structure with abiraterone. The two drugs are distinguished by their C17
moieties – the benzamidazole ring of galeterone – and the 3-pyridyl structure of
abiraterone. These differences may explain why galeterone has been reported to have more
direct effects on AR
However, abiraterone is metabolized in vivo to Δ4-abiraterone (D4A), which more
potently than abiraterone inhibits the androgen axis12, and 5α-abiraterone, which in contrast
is an AR agonist that promotes tumor progression13. The differing activities of abiraterone
and galeterone may be due to their respective steroidal metabolites that interact with
steroidogenic enzymes and AR, which in turn may thus far have led to an incomplete
accounting of the context and activities of the parent drugs. However, metabolites of
galeterone along steroidogenic pathways have not yet been identified (Fig. 20).
The aim of this chapter is to describe in vitro and in vivo galeterone metabolism by
steroidogenic enzymes and to evaluate galeterone metabolite activity in prostate cancer.
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Figure 20. Steroidogenic metabolism of galeterone
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5.2.

Experimental Section

5.2.1. Cell lines and chemicals
LNCaP, 293T and VCaP cells were purchased from the American Type Culture
Collection (Manassas, VA) and maintained in RPMI-1640 (LNCaP) or DMEM (293T and
VCaP) with 10% FBS. LAPC4 cells were kindly provided by Dr. Charles Sawyers
(Memorial Sloan Kettering Cancer Center, New York, NY) and grown in Iscove’s Modified
Dulbecco’s Medium with 10% FBS. All experiments with LNCaP and VCaP cells were
done in plates coated with poly-DL-ornithine (Sigma-Aldrich, St. Louis, MO). A 293T cell
line stably expressing human CYP17A1 was generated by transfection with plasmid
pcDNA3-c17 (a generous gift of Dr. Walter Miller, University of California, San Francisco)
and selection with G418 as described14. Cell lines were authenticated by DDC Medical
(Fairfield, OH) and determined to be mycoplasma-free using the following primers:
5’-ACACCATGGGAGCTGGTAAT-3’ and
5’-GTTCATCGACTTTCAGACCCAAGGCAT3’.
Dutasteride was purchased from Medkoo Biosciences (Chapel Hill, NC). Methanol,
acetonitrile, water, and formic acid were LC–MS grade and all were from Fisher Scientific
(Fair Lawn, NJ). Double charcoal-stripped human serum was from Golden West Biological
Inc. (Temecula, CA). Galeterone and D4G were purchased from Shanghai Forever
Synthesis Co., Ltd. (Shanghai, China). 3-keto-5α-galeterone, 3α-OH-5α-galeterone, 3βOH-5α-galeterone, 3-keto-5β-galeterone, 3α-OH-5β-galeterone, and 3β-OH-5β-galeterone
were synthesized in the laboratory of Dr. Richard Auchus, University of Michigan Medical
School.

95

5.2.2. Cell line metabolism
To test the hypothesis that galeterone would be metabolized by steroidogenic
enzymes to D4G, and 6 metabolites downstream of D4G, two prostate cancer cell lines,
LNCaP (which expresses mutant 3βHSD1 with high enzyme activity)

15

and LAPC4

(which expresses wild-type 3βHSD1 with low enzyme activity) 15, were used. Cells were
seeded and incubated in 12-well plates with 0.2 million cells/well for ~24 h and then
incubated with 0.1µM of either galeterone, D4G or 3-keto-5α-Gal (5αG) for 24 and 48 hr.
Media were collected at the two time points and were subjected to LC-MS analysis. This
experiments was performed in triplicate for each drug and was repeated in three biological
repeats.
To confirm that steroidogenic enzymes directly metabolize galeterone, 3βHSD1,
SRD5A1, or AKR1C2 was overexpressed in HEK-293 cells, which were then treated with
galeterone, D4G, or 5αG respectively. Media were collected 3 and 6 hours after the
treatment and were subject to LC-MS analysis.
To study the effect of blocking SRD5A1 on D4G metabolism, LAPC4 cells (which
express SRD5A1) were incubated with D4G with and without SRD5A1 inhibitors
(dutasteride and LY191704) or short hairpin RNAs targeting SRD5A1. Media samples
were collected 3 and 6 hours and were subjected to LC-MS analysis.
5.2.3. In vivo metabolism
To study the metabolism of galeterone in vivo, male NSG mice, 6 to 8 weeks of age
were obtained from the Cleveland Clinic Biological Resources Unit. All mouse studies
were conducted under a protocol approved by the Cleveland Clinic Institutional Animal
Care and Use Committee. Mice (n = 3 mice/group) were injected intraperitoneally with
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100 µL solution containing 0.15 mmol/kg of either galeterone, D4G, 3-keto-5α-Gal 3αOH-5α-Gal, or 3β-OH-5α-Gal. Blood was collected 2 and 4 hrs after injection, centrifuged
at 10,000 rpm, and the sera were stored at -80ºC for LC-MS analysis.
5.2.4. Effects of galeterone metabolites on steroidogenic enzyme activity
To study the effect of galeterone metabolites on steroidogenic enzymes, three cell
lines were used: HEK-293, LNCaP, and LAPC4. HEK-293 cells overexpressing CYP17A1
were treated with [3H]-pregnenolone in the presence of D4A (0.1, 1 and 10 nM), or
galeterone and its metabolites (1, 10 and 100 nM), for 3 and 6 h, and conversion to DHEA
was assessed by HPLC. LNCaP cells were treated with [3H]-DHEA and the indicated
drugs at 0.1, 1.0, and 10 μM for 24 and 48 h, and the conversion to AD was assessed by
HPLC. LAPC4 cells were treated with [3H]-AD and 1, 5 and 10 µM of the indicated drugs
for 8 and 24 h, and flux to 5α-dione was assessed by HPLC. All experiments went through
the same protocol as follows: 12-well plates with 0.2 million cells/well for ~24 h and then
incubated with indicated drugs or a mixture of radioactive ([3H]-labeled) and nonradioactive steroids (final concentration, 100 nM; ~1,000,000 cpm/well; PerkinElmer,
Waltham, MA) at 37ºC. Aliquots of medium were collected at the indicated times.
5.2.5. AR competition assay
The affinity of galeterone and its metabolites for mutated or wild-type AR were
assessed as follows: LNCaP (mutated AR) or LAPC4 (wild-type AR) were cultured in
serum-free medium for 48 h and then incubated with [3H]-R1881 with or without the drugs
(D4A, galeterone, D4G, 5α-Gal) for 30 min. Cells were washed with 1X PBS 4 times and
0.9% NaCl solution twice before lysis with RIPA buffer. Intracellular radioactivity was
measured with a Beckman Coulter LS60001C liquid scintillation counter and normalized

97

to the protein concentration as detected with a Wallac Victor2 1420 Multilabel counter
(Perkin Elmer).
5.2.6. Effects of galeterone metabolite on AR-regulated gene expression
To study the effect of galeterone metabolites on AR target gene expression. LNCaP
and LAPC4 cells were serum starved for 48 h before treatment with DHT (0.5 or 0.1 nM,
respectively) and 1 μM of galeterone, D4G, 5α-Gal, D4A or 5α-Abi for 24 h. Cells were
starved with phenol red-free and serum-free medium. RNA was extracted with a GenElute
Mammalian Total RNA miniprep kit (Sigma-Aldrich). cDNA was synthesized from 1 µg
RNA in a reverse transcription reaction using the iScript cDNA Synthesis Kit (Bio-Rad,
Hercules, CA). Quantitative PCR (qPCR) analysis was conducted in triplicate with primers
for PSA, TMPRSS2, and RPLPO (housekeeping gene) in an ABI 7500 Real-Time PCR
machine (Applied Biosystems) using iTaq Fast SYBR Green Supermix with ROX (BioRad) in 96-well plates at a final reaction volume of 20 µL. Accurate quantitation of each
mRNA was achieved by normalizing the sample values to RPLPO and to vehicle-treated
cells.
5.2.7. Mouse xenograft studies
All mouse studies were conducted under a protocol approved by the Cleveland
Clinic Institutional Animal Care and Use Committee. Male NSG mice, 6 to 8 weeks of age
were obtained from the Cleveland Clinic Biological Resources Unit.
In order to study the efficacy of D4G as a tumor suppresser, D4G was compared
with galeterone. 107 VCaP cells were injected subcutaneously with Matrigel into surgically
orchiectomized NSG mice that were implanted with 5 mg 90-day sustained-release DHEA
pellets (Innovative Research of American, Sarasota, FL) to mimic human physiology. Once
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tumors reached 300 mm3 (length × width × width × 0.52), the mice were arbitrarily
assigned to vehicle (n=11), galeterone (n=11), or D4G (n=11) treatment groups. Galeterone
and D4G (0.15 mmol/kg in 0.10 mL 15% ethyl alcohol in safflower oil) were administered
via 5 mL/kg intraperitoneal injection twice daily, 5 days per week for up to 20 days. Control
groups were administered 0.10 mL of a solution of 15% ethyl alcohol in safflower oil. Once
the treatment was started, tumor volume was measured with calipers three times per week,
and time to increase in tumor volume by 20% was determined. Mice were sacrificed at
treatment day 20. The significance of the difference between treatment groups was
assessed by Kaplan-Meier survival analysis using a log-rank test in SigmaStat 3.5.
Student’s t-test was used to determine significance between different treatments.
To evaluate whether 3-keto-5α-Gal enhances tumor growth, it was compared with
3-keto-5α-Abi which has been shown previously to enhance tumor growth in mice13. 107
VCaP cells were injected subcutaneously with matrigel. Once tumors reached 100 mm3
(length × width × width height × 0.52), mice were surgically orchiectomized and arbitrarily
assigned to vehicle (n=9), 3keto-5α-Abi (n=9), or 3keto-5α-Gal (n=9) treatment groups.
3keto-5α-Abi and 3keto-5α-Gal (0.15 mmol/kg in 0.10 mL 15% ethyl alcohol in safflower
oil) were administered via 7.55 mL/kg intraperitoneal injection once daily, 5 days per week
for 24 days. Control groups were administered 0.1 mL of a solution of 15% ethyl alcohol
in safflower oil. Tumor volume was measured every other day, and time to increase in
tumor volume by 30% was determined. Mice were sacrificed at treatment day 24. The
significance of the difference between treatment groups was assessed by Kaplan-Meier
survival analysis using a log-rank test in SigmaStat 3.5. Student’s t-test was used to
determine significance.
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5.2.8. High-performance liquid chromatography (HPLC)
Collected medium from the experiments in section 5.2.4. was treated with 1,000
units of β-glucuronidase (Helix pomatia; Sigma-Aldrich) at 37°C for 2 h, extracted with
860 µL ethyl acetate:isooctane (1:1), and concentrated under nitrogen gas. HPLC analysis
was performed on a Waters 717 Plus HPLC or an Agilent 1260 HPLC. Dried samples were
reconstituted in 100 µl 50% methanol and injected into the instrument. Steroids were
separated on a Kinetex 100 × 2.1 mm, 2.6 µm particle size C18 reverse-phase column
(Phenomenex, Torrance, CA) using a methanol/water gradient at 30°C. The column
effluent was analyzed using a dual-wavelength UV-visible detector set at 254 nm or βRAM model 3 in-line radioactivity detector (IN/US Systems, Inc.) and Liquiscint
scintillation cocktail (National Diagnostics, Atlanta, GA). All HPLC studies were
conducted in triplicate and repeated at least 3 times in independent experiments.
5.2.9. Mass spectrometry
Galeterone and its seven steroidal metabolites were determined using the validated
LC-MS method for the determination of abiraterone and its seven structurally related
metabolites16 with slight modifications. The mobile phase consisted of 30% A (0.2% formic
acid in water) and 70% B (0.2% formic acid in methanol:acetonitrile, 60:40). Separation
of the metabolites was achieved using a Zorbax Eclipse plus 150 x 2.1 mm, 3.5µm C18
column (Agilent, Santa Clara, CA) at a flow rate of 0.2 ml/min. Drug metabolites were
ionized using electrospray ionization in positive ion mode.
The LC-MS method was applied to analyze cell media and mouse serum samples.
To 200 µL media, 40 µL internal standard (abiraterone) was added, then the analytes were
extracted with 2 ml TMBE (Sigma Aldrich, St. Louis, MO), the TMBE was evaporated,
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and the sample reconstituted with 200 µL (methanol:H2O; 1:1). The standard curves were
prepared in media. The metabolites were extracted from 20 µl mouse serum by adding 280
µl methanol containing the internal standard. The samples were then vortexed and
centrifuged at 12,000 rpm for 10 min, and 200 µl supernatant was transferred to the HPLC
vial.
To extract the metabolites from the tumor, tumor (28.3-63.3 mg) was homogenized
with 750 µl LC-MS grade water. Then 75 µl internal standard (abiraterone) was added to
the mixture, the metabolites were extracted from the homogenate using 2.5 ml TMBE, the
organic layer was then evaporated, and the samples were reconstituted with 300 µl
methanol: water (50:50).
5.3.

Results and Discussion

5.3.1. Galeterone metabolite separation by LC-MS/MS
The modifications of abiraterone validated LC-MS/MS method resolved all
galeterone metabolites (Fig 21). The method was applied to detect galeterone metabolites
in cell media, mouse serum, and mouse tumor
5.3.2. In vitro metabolism of galeterone by steroidogenic enzymes
After treating LNCaP and LAPC4 cells with galeterone for 24 or 48h, galeterone
metabolites including D4G, 5αG, 3α-OH-5αG and 3β-OH-5αG were detected by LC-MS.
Metabolism of galeterone to D4G and to subsequent 5α-reduced metabolites was more
robust in LNCaP than LAPC4 cells (Fig. 22A&B), consistent with the known high 3βHSD
enzyme activity in LNCaP cells. D4G was converted to 5αG, 3α-OH-5αG, and 3β-OH5αG but not back to galeterone, indicating that conversion from galeterone to D4G is
irreversible. 5αG treatment led to the production of 3α-OH-5αG and 3β-OH-5αG but not
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D4G or galeterone. No 5β-reduced metabolites were detectable, consistent with the
absence of 5β-reductase activity in prostate cancer cell lines.
Expression of 3βHSD1 in HEK-293 cells permitted the conversion from galeterone
to D4G (Fig. 23A). Similarly, expression of SRD5A1 or SRD5A2 resulted in the
conversion of D4G to 5αG (Fig. 23B). Expression of AKR1C2, the major enzyme that
converts endogenous 3-keto steroids such as DHT to their 3α-OH metabolites, enabled the
conversion from 5αG to 3α-OH-5α-Gal in a time- and concentration-dependent manner
(Fig. 23C). In LAPC4 cells with endogenous SRD5A1 activity, the SRD5A inhibitor
LY191704 or dutasteride blocked the conversion from D4G to 5αG (Fig. 24A). Stable
SRD5A1 knockdown with short hairpin RNAs similarly ablated metabolism from D4G to
5αG (Fig. 24B). Together, these data support the hypothesis that galeterone undergoes
direct metabolism by steroidogenic enzymes, similar to endogenous steroids and the
structurally related drug, abiraterone.
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Figure 21. LC-MS separation of all galeterone metabolites. The results were obtained by
injecting 10 μL of 50 ng/mL standard mixture of galeterone and its metabolites.
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Figure 22. Metabolism of galeterone and its metabolites in A, LNCAP and B, LAPC4
cells
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Figure 23. Steroidogenic enzymes required for galeterone metabolism. Overexpressing
of A, 3βHSD1; B, SRD5A; and C, AKR1C2 resulted in converting the precursors.
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Figure 24. Effect of blocking SRD5A1 on D4G metabolism. D4G conversion was
blocked A, Pharmacologically or B, genetically.
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5.3.3. In vivo metabolism
Galeterone and its metabolites were injected into NSG mice to determine its
metabolism in vivo (Fig. 25). In addition to D4G and the three 5α-reduced metabolites,
three 5β-reduced metabolites – 5βG, 3α-OH-5βG and 3β-OH-5βG – were detected in
mouse serum after galeterone injection. Furthermore, injecting any one 5αG-compound led
to detection of all three 5α-reduced metabolites, which indicates that 5αG, 3α-OH-5α-G
and 3β-OH-5α-G are interconvertible in vivo. In subsequent studies, we focused on D4G
and the 5α-reduced metabolites because 5α-reduction leads to the formation of a planar
structure, as occurs with the most potent endogenous androgen, DHT17,18. On the other
hand, 5β-reduction of 3-keto steroids introduces a 90° bend, which generally inactivates
steroid hormones and facilitates their clearance.
5.3.4. Effects of galeterone metabolites on steroidogenic enzyme activity
Galeterone was reported to be more potent than abiraterone against CYP17A1
expressed in E. coli7,19. However, the comparative effects of their respective metabolites
on steroidogenic enzymes is not known. D4A, the abiraterone metabolite that most potently
inhibits steroidogenesis, was compared with galeterone and its metabolites12. In HEK-293
cells stably expressing CYP17A1, D4A, at a concentration of 10 nM, completely blocked
CYP17A1-catalyzed conversion of [3H]-pregnenolone to DHEA. Galeterone and its
metabolites were approximately 100-fold weaker in blocking the production of DHEA
(Fig. 26A). This result indicated that galeterone and its metabolites are 100-fold less potent
than D4A in blocking CYP17A1 activity. In LNCaP cells, which possess high 3βHSD
enzyme activity, galeterone inhibited the conversion of [3H]-DHEA to Δ4-androstenedione
(AD), comparably to D4G and D4A (Fig. 26B). Conversion from D4G to 5αG slightly
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reduces the capacity to inhibit 3βHSD1 activity. D4G was more potent than galeterone and
comparable to D4A in inhibiting SRD5A activity, as assessed with the conversion of [3H]AD to 5α-dione in LAPC4 cells (Fig. 26C).
5.3.5. The effect of galeterone and its metabolites on AR and AR signaling
Galeterone has been reported to directly bind to and enhance the degradation of
AR10. To determine the affinity of galeterone and its metabolites for AR, a competition
assay was performed. The affinity of D4G for mutant AR (expressed in LNCaP, T877A)
and wild-type AR (expressed in LAPC4 cells) was greater than that of galeterone,
comparable to that of D4A, and comparable to or slightly greater than that of 5αG (Fig.
27A&B). To assess the functional consequences of galeterone and its metabolites, their
effects on expression of androgen-responsive genes were investigated. Galeterone and
D4G inhibited DHT-induced AR-target gene expression in LNCaP and LAPC4 cells,
comparable to D4A (Fig. 27C&D). To a lesser extent, 5αG also suppressed DHT-induced
gene expression. Notably, however, 5αG somewhat increased basal PSA expression in the
absence of DHT in LNCaP cells. Compared with 3-keto-5α-abiraterone (5α-Abi), a weak
AR agonist, 5αG is an even weaker agonist (Fig. 27C&D). Taken together, these data
indicate that the conversion from galeterone and D4G by SRD5A to 5αG may lead to a
diminished effect on AR stability and AR-responsive gene expression.
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Figure 25. Galeterone metabolism in vivo. A, Galeterone; B, D4G; C, 3-keto-5α-Gal; D,
3α-OH-5α-Gal; E, 3β-OH-5α-Gal.
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Figure 26. Effect of galeterone metabolites on steroidogenic enzyme activity. A, effect on
CYP17A; B, 3βHSD1; and C, SRD5A1
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Figure 27. Effect of galeterone metabolites on AR signaling. Affinity of the metabolites
to AR in A, LNCAP and B, LAPC4 cells. The effect of the metabolites on AR regulated
gene expression in C, LNCAP and D, LAPC4 cells.
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5.3.6. Galeterone metabolite effects on tumor progression in a mouse xenograft
model
The effect of D4G on tumor growth in a xenograft mouse model was studied
because D4G was comparable to or slightly better than galeterone in blocking
steroidogenesis and suppressing AR regulated gene expression. VCaP xenografts were
grown subcutaneously in orchiectomized mice with DHEA pellet implantation to mimic
human adrenal androgen physiology. Time from initiation of treatment with D4G,
galeterone, or vehicle to tumor progression (>20% increase in tumor volume) was assessed
by generating Kaplan–Meier survival curves, and comparing treatment groups with the logrank test. Galeterone inhibited xenograft growth (vehicle vs. galeterone, p=0.01).
Xenograft progression was also significantly delayed in the D4G group compared with the
vehicle group (p=0.02) and was no different when compared to the galeterone group (D4G
vs galeterone, p=0.98) (Fig. 28). LC-MS analysis for galeterone and its metabolites in
serum and tumors collected at the study end confirmed that conversion to downstream
galeterone steroidal metabolites is detectable in both xenografts and serum (Fig. 29A&B).
Due to 3-keto-5α-Gal ability to stimulate AR regulated gene expression, the effect
of 3-keto-5α-Gal activity on xenograft tumor progression was studied in orchiectomized
mice injected subcutaneously with VCaP xenografts. The mice were assigned to vehicle,
3-keto-5α-Gal, or 5α-Abi. Time from initiation of treatment to tumor progression (>30%
increase in tumor volume) was assessed by generating Kaplan–Meier survival curves and
comparing treatment groups with the log-rank test (Fig 30). Tumors from vehicle-treated
mice did not differ from those receiving 3-keto-5α-Gal (P=0.125), nor did tumors from
mice receiving 3-keto-5α-Gal treatment differ from those receiving 5α-Abi (P=0.20).
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Figure 28. Survival curve of mice treated with galeterone or D4G. Galeterone and
D4G will delay the growth of mouse xenograft compared to vehicle.
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Figure 29. Metabolite percentages in tumor and serum. The results were obtained from
LC-MS analysis for A, tumor samples and B, serum samples.
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Figure 30. Effect of 5α-galeterone on tumor growth. 5α-Abi and 5α-Gal promote tumor
progression in mouse xenograft.
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5.4.

Conclusions
Galeterone undergoes steroidogenic metabolism to generate D4G, 3-keto-5α-Gal,

3-keto-5β-Gal and 4 other steroidal metabolites. This pathway was confirmed both in vitro
and in vivo. Galeterone metabolites had opposing effects on prostate tumors in the
xenograft models. Whereas D4G inhibits steroidogenic enzymes, AR-regulated gene
expression, and tumor progression, its conversion resulted in loss of activity and generation
of 3-keto-5α-Gal, which promoted AR target gene expression and enhanced tumor growth.
Galeterone follows the same steroidogenic metabolism as abiraterone, which suggests a
novel pathway for metabolism of steroidal 3β-OH Δ5 analogues, which should be
considered in future drug design.
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CHAPTER VI
PROJECT CONCLUSIONS AND FUTURE DIRECTIONS

CYP17A1 is a clinically validated target for the treatment of CRPC1-3. Nonsteroidal and steroidal CYP17A1 inhibitors are both undergoing pharmacologic and
clinical development; however, the consequences of using steroidal vs. non-steroidal drugs
are not well understood. Here, I determined that abiraterone and galaterone, Δ5, 3βhydroxyl steroidal drugs, are converted to at least seven steroidal metabolites that are either
3-keto Δ4, (1 metabolite) 5α-reduced (3 metabolites), or 5β -reduced (3 metabolites) in vitro
and in vivo, and have important downstream consequences on the androgen axis. Therefore,
steroidogenic metabolism of drugs with the Δ5, 3β-hydroxyl structure appears to be a class
effect, instead of being a property that is unique to a single drug. The activity of these
metabolites is a critical issue with broad consequences for drug development across
steroid-dependent diseases.
The development of the LC-MS/MS method that distinguished the metabolites gave
a clear picture and understanding of abiraterone and galeterone metabolism. Despite its
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novelty in separating all the diasteroisomers, the method did not require any sophisticated
techniques and was developed using materials that are available in any analytical lab.
An important property that distinguishes galeterone from abiraterone is that
galeterone has been reported to have direct properties as an AR antagonist and degrader,
while CYP17A1 is generally thought to be the main direct target of abiraterone. However,
conversion of galeterone by 3βHSD and SRD5A to other metabolites that are formed in
vitro and in vivo, with varying biochemical activities, clearly has consequences on
steroidogenic enzymes and direct effects on AR. Importantly, D4G and 5αG bind AR more
potently than galeterone, although both of these metabolites downstream of 3βHSD have
divergent effects on AR.

Interestingly, despite the increased affinity for AR and

maintaining AR enhanced degradation activity, the activity of D4G in a xenograft model
of CRPC was no better than that of galeterone. It is possible that any increased anti-tumor
xenograft activity by D4G was reversed because it is one metabolic step closer to 5αG,
resulting in higher intratumoral concentrations of the latter. This result raises the possibility
that SRD5A inhibition to block 5αG synthesis might be beneficial.
These findings also suggest that the design and use of steroid-based drugs for
prostate cancer should consider the relative activities of steroidogenic enzymes in prostate
cancer. For example, abiraterone and galeterone are rapidly converted to their steroidal
metabolites in cells that have high, but not low, 3βHSD1 activity. A published head-tohead comparison of galeterone vs. abiraterone in LAPC4 xenografts demonstrated
galeterone to have superior activity4. However, 3βHSD1 activity is low in LAPC4 cells,
and therefore this comparison likely was more selectively focused on galeterone and
abiraterone. The consequences of downstream galeterone metabolites are more likely to
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be seen in cancer models and patients that have the 3βHSD1 N367T missense that
accumulates and results in high activity5.
The presence of steroidal abiraterone metabolites in patients was confirmed by
analyzing samples from patients who underwent treatment with abiraterone acetate6,7. The
metabolite levels can be altered by combining abiraterone acetate with other drugs like
SRD5A inhibitors which may maximize the benefits of the treatments. Although increasing
the standard dose of abiraterone acetate resulted in increasing D4A levels, it also increased
5α-Abi and therefore maintained the percentage of both the good and the bad metabolites.
In prostate tissue, which expressed high SRD5A1activity, the D4A level was lower than
the 5α-Abi level. All these results indicate that new strategies are critically needed in
treatment options that involve abiraterone acetate.
Galeterone is under study in clinical trials; therefore, this work was limited by
patient sample availability; as a result it was not possible to assess the metabolites in
clinical samples.

However, given the similar metabolic behavior of galeterone and

abiraterone in prostate cancer models, in vivo and with specific steroidogenic enzymes, it
is highly likely that the concentrations of galeterone metabolites are significant and similar
to abiraterone metabolites in patients.
In summary, our results provide a more complete picture of abiraterone and
galeterone metabolism and activity. These findings demonstrate that metabolism by
steroidogenic enzymes is a class effect of Δ5, 3β-hydroxyl drugs that should be accounted
for in preclinical and clinical drug development and distinguishes these agents from nonsteroidal inhibitors. The levels of these metabolites and their respective activities are
determined by the expression and activity of endogenous steroidogenic enzymes, including
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3βHSD and SRD5A. These findings must be considered for the development of better
treatment strategies.
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